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Introduction and thesis outline 
Imaging plays a crucial role in cancer care; it is used to diagnose, to guide biopsies, to monitor 
treatment response, to plan surgical interventions, and to predict the course of the disease[1, 
2]. Computed tomography, magnetic resonance imaging, X-ray, and ultrasound, are routinely 
used imaging modalities that mainly provide anatomical information [1]. The more recently 
introduced positron emission tomography and single positron emission computed tomography 
provide functional information [3]. Advances in all these techniques have led to more precise, 
faster, and less-invasive imaging [4, 5]. However, all of these image modalities come with their 
own limitations with respect to resolution, sensitivity, and contrast generation [3], rendering 
them unsuitable for certain applications [6]. Moreover, apart from X-ray and ultrasound, these 
techniques are costly and real-time imaging is challenging. A new range of medical imaging 
technologies is being developed and used to fill this gap: optical imaging techniques [2]. 
Optical imaging encompasses a variety of techniques that use light in the ultraviolet range 
(315-400 nm), the visible range (400-700 nm), the near infrared (NIR) range (700-1400 nm) 
and light in the short wave infrared (SWIR) range (1400-3000 nm) [7] to provide molecular, 
morphological, and functional information of cells or tissues. These techniques include endos-
copy, NIR fluorescence imaging, optical coherence tomography (OCT), photo-acoustic imaging, 
confocal laser endomicroscopy, diffuse spectroscopy, and Raman spectroscopy. Although the 
advantages of optical techniques depend heavily on the used technique and field of applica-
tion, some general advantages are: good contrast in soft tissue, high resolution (from 15 mm for 
photo-acoustic imaging up to the submicron range for Raman spectroscopy [8]), non-ionizing 
nature, cheap and relatively easy to handle equipment [3, 9, 10]. The biggest disadvantages 
are the limited penetration depth (ranging from several hundreds of micrometers for Raman 
spectroscopy to several centimeters for photo-acoustic imaging [8]) and limited field of view 
(from point measurements for Raman spectroscopy up to 250 mm for fluorescence guided 
surgery [8]). 
The type of contrast that is generated by optical imaging depends on the type of interac-
tions between light and tissue that are recorded. Light that interacts with tissue undergoes 
different processes: reflection, absorption, and scattering [11]. All these forms of light-tissue 
interaction are studied in this thesis, using different techniques: OCT, reflectance spectroscopy 
and fluorescence lifetime imaging. This introduction provides a short overview of these three 




Full fi eld opti cal coherence tomography
Opti cal coherence tomography can be seen as the opti cal analog of ultrasound, but rather 
than back-scatt ered sound, it detects back-refl ected light [12]. The resoluti on in comparison to 
ultrasound is 10-50 ti mes bett er, and usually lies in the range of 1-20 µm in axial and transverse 
directi on [13, 14]. Like ultrasound, OCT is able to image non-invasively and non-destructi vely.
Standard elements of an OCT device include a light source, an interferometer, a reference 
arm and a detector. Light coming from the source is split by the interferometer into 2 paths of 
light: one path leads to the sample, while the other goes to the reference arm – a mirror. When 
light from the reference arm and the sample have traveled the same distance, an interference 
patt ern arises. Areas in the sample exhibiti ng great refl ecti vity, such as collagen fi brils, will 
consequently generate greater interference and thereby a larger signal than areas with lower 
refl ecti vity, such as adipose ti ssue. The combined signal is collected by the detector and an 
image, typically cross-secti onal, can be reconstructed. 
For ti me domain OCT (TD-OCT), the reference arm is translated longitudinal in ti me to 
determine the depth of the ti ssue-scatt ered light. TD-OCT typically uses a broadband light 
source – as the low coherence length translates to a high axial resoluti on [15] – in the NIR 
wavelength range to achieve a larger sensing depth. Frequency domain OCT (FD-OCT) either 
uses a combinati on of tunable laser with a photodiode detector or a broadband wavelength 
with a spectrometer [16]. The acquired signal contains informati on on the enti re depth of one 
point, and subsequently the depth profi le can be constructed by the Fourier transformati on. 
The main advantage of this method is that the reference arm is stati c instead of moving, which 
allows for much faster scanning speed [17]. 
Both FD-OCT and TD-OCT systems are commercially available and are standard-of-care 
in ophthalmology [18]. Also in interventi onal cardiology, where OCT has been integrated in 
catheters, the use of OCT is rapidly growing. With the development of new modaliti es, like full 
fi eld OCT (FF-OCT), other fi elds of interest are being explored, including the fi eld of oncology 
[14, 19]. 
In this thesis we looked at FF-OCT: an opti cal biopsy technique with high resoluti on, that 
provides en face images. Figure 1 shows the schemati c and actual setup of one of the FF-
OCT system (LLTech, France) that we used. It is a ti me domain system that uses a 150-watt  
white halogen light source with a central wavelength of 700 nm with spectral width of 125 nm. 
Furthermore, it uses a Linnik-type interferometer that allows for the parallel acquisiti on of all 
pixels on a 2D camera [20, 21]. Resoluti on is 1 µm in 3D. In depth imaging is possible as well, but 
in scatt ering ti ssue this is limited to approximately 500 µm. So far, several studies report the use 
of FF-OCT, i.e. on ocular, skin and brain ti ssue [20–22]. These fi rst studies showed that normal 
structures can be recognized and diff erences can be seen when comparing normal ti ssue to 
1
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tumor ti ssue. This is largely due to changes in the architecture of the ti ssue, as the endogenous 
contrast of cell nuclei is not suffi  cient to be detected with FF-OCT. 
Refl ectance spectroscopy
Refl ectance spectroscopy measures the spectral response of ti ssue-light interacti on. These 
ti ssue-light interacti ons provide informati on about the ti ssues’ absorpti on and scatt ering prop-
erti es. Absorpti on of photons can occur without re-emitti  ng another photon and is wavelength 
dependent. By looking at the light that is re-captured, and thus not absorbed, informati on on 
chromophores – the absorbers in the ti ssue – is acquired. In the visible range, blood (oxygen-
ated and de-oxygenated hemoglobin) is the main absorber in biological ti ssue. In the NIR range, 
fat and water are the main absorbers. Light is also absorbed by other chromophores such as 
bilirubin and beta-carotene, depending on the ti ssue type. Light is scatt ered through interac-
ti ons with the underlying cellular structures, such as cell nuclei. Informati on on the size and 
density of these structures provide an insight in the ti ssues’ morphology. 
Most commonly, refl ectance spectroscopy illuminates the ti ssue with a broadband white 
light source through one or multi ple opti cal fi bers, and captures the returning light through 
diff erent or the same fi ber(s). A spectrometer collects the returning light and converts it into 
a spectrum. In literature, several methods are described to analyze the acquired refl ectance 
spectra. One method is to use a physical analysis method: a priori knowledge of the ti ssue com-
ponents is used to extract and quanti fy physiological informati on from the obtained spectra 
[24–27].
Numerous studies used the absorpti on and scatt ering properti es of ti ssue to show dif-
ferences between normal and tumor ti ssue, for example in lymph nodes, liver and lung. In 










Figure 1.  A schemati c set-up of the FF-OCT system (based on [23])
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higher blood volume and lower scatt ering parameters [28–30]. These diff erences could give 
physicians feedback on suitable biopsy locati ons or tumor margins.
In this thesis we looked at single fi ber refl ectance (SFR) spectroscopy: the same single fi ber 
delivers the outgoing and collects the returning light (Figure 2). As a consequence, refl ectance 
spectra can be measured through a biopsy needle. Measurement depth is shallow, as it is 
related to the fi ber diameter.
Fluorescence lifeti me measurements
Certain molecules have the ability to absorb light at a parti cular wavelength and emit light at a 
longer wavelength; this is called fl uorescence. Aft er light absorpti on, almost all molecules relax 
to the lowest vibrati onal state of the fi rst exited state, from which molecules return to their 
ground energy state. Returning to ground state occurs either via non-radiati ve decay or radia-
ti ve decay (non-harmful photons), the latt er is responsible for fl uorescence. The average ti me 
it takes a molecule to radiati vely decay aft er having been excited is the fl uorescence lifeti me. 
The lifeti me is infl uenced by intrinsic characteristi cs of the fl uorophore itself, the environment 
it is in [31] – such as pH, local viscosity, polarity and temperature – and interacti ons with other 
fl uorophores, while it is largely insensiti ve to diff erences in fl uorophore concentrati on and 
fl uorescence intensity [32]. Therefor lifeti me provides complementary functi onal informati on 
to fl uorescence intensity imaging. 
To measure fl uorescence lifeti me, typically in the order of hundreds of picoseconds to 
hundreds of nanoseconds, dedicated equipment is necessary. Similar to OCT, fl uorescence 
lifeti me can be measured using a ti me-domain and frequency-domain approach. TD measure-
ments are either performed by ti me gated image intensifi ers or ti me correlated single photon 
counti ng. The principle however is very similar: a short light pulse is emitt ed to the ti ssue, for 
example with a high frequency pulsed laser, and returning photons are detected through a 







Figure 2. Single fi ber refl ectance spectroscopy
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of the photons are determined and a lifeti me can be calculated from the slope of the decay 
curves. FD measurements are related to TD via the Fourier transform. A sinusoid light wave 
with a certain frequency is emitt ed. The re-emitt ed light, detected with photomulti plier tubes 
or charge-coupled devices, occurs at the same frequency, but with a phase shift  and reducti on 
in amplitude. From these parameters, the lifeti me can be calculated [31, 32]. 
Fluorescence lifeti me is widely used in preclinical research and clinical applicati ons of fl uo-
rescence lifeti me are also being explored, for example to investi gate the effi  cacy of targeted 
therapy [33] or to diff erenti ate between tumor and normal ti ssue [34].
APPLICAtIons
Pancreati c cancer
Pancreati c cancer is the 4th leading cause of cancer death in the Netherlands, while it is ranked 
10th in incidence [35]. The 5-year survival rate is only 6%, mainly due to late detecti on as early-
stage pancreati c cancer is usually clinically silent [36, 37]. The only curati ve treatment for the 
most prevalent carcinoma type of the pancreas – infi ltrati ng ductal adenocarcinoma (IDAC) – is 
surgery, but only about 20% of pati ents are eligible for this treatment [36]. These are pati ents 
with a tumor that is not yet metastasized, has no severe vascular infi ltrati on and is thought to 
be completely resectable [38]. Currently neoadjuvant therapy – chemotherapy or radiati on – to 
downsize the primary tumor and treat micrometastati c disease prior to resecti on gains more 
interest [39]. This does however require a biopsy to pathologically confi rm the presence of 
tumor. Subsequently, if the tumor is surgically removed, it is important to remove the enti re 
tumor. In this thesis we looked at two diff erent applicati ons of opti cal techniques for pancreati c 
cancer: (1) single fi ber refl ectance spectroscopy to guide biopsies, and (2) FF-OCT to diff eren-




















Figure 3. Schemati c setup (used in this thesis) to measure fl uorescence lifeti me
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Patients suspected of a pancreatic lesion, usually are subjected to a CT scan, which is best 
for disease staging and provides 80% accuracy for prediction of resectability [36]. For cytologi-
cal diagnosis, endoscopic ultrasound fine needle aspiration (EUS-FNA) is most commonly used: 
a relatively safe procedure with high specificity. However, its high sampling error results in a 
low-negative predictive value and requires an on-site cytopathologist [40]. Furthermore, when 
(peritumoral) pancreatitis is present – which frequently occurs – the accuracy of EUS-FNA drops 
considerably. In this thesis we looked at the feasibility and added value of SFR spectroscopy to 
guide the gastroenterologist during the EUS-FNA procedure, with an ultimate goal to improve 
its accuracy.
Patients who are eligible for surgery, typically undergo a pancreatoduodenectomy (for 
tumors located in the pancreatic head) or a distal pancreatectomy (for tumors located in the 
body and tail of the pancreas). One important prognosticator of the 5-year survival rate after 
surgery are clear (R0) resection margins [41–43]: the resection specimen should be clear from 
tumor within 1 mm of the margins. However, due to the dispersed growing pattern of IDACs, 
its anatomical proximity to vital surrounding structures, and the presence of peritumoral 
inflammation, positive margins frequently occur: up to 60-80% [42–47]. At the moment, dur-
ing surgery, surgeons mostly have to rely on visual inspection and palpation. In this thesis we 
imaged normal and pathological pancreatic tissue using FF-OCT, and looked at the accuracy 
with which the pathologists could distinguish these.
Fertility preservation
Advanced screening methods and novel treatment modalities have led to an improved 
overall survival for cancer patients, making the long-term adverse effects of treatment more 
important. Significant consequences of chemo- and pelvic radiotherapy in premenopausal 
women are decreased fertility or even infertility [48], leading to a lower quality of life [49, 50]. 
Therefore, fertility preservation is extremely important and has high priority. Current available 
techniques include embryo and oocyte cryopreservation, ovarian transposition, and ovarian 
tissue cryopreservation [51]. In ovarian transplantation – only suitable for patients with pelvic 
malignancies requiring pelvic radiotherapy – the ovaries are moved outside the radiation field 
[52]. Patients receiving chemotherapy are not benefited by ovarian transposition; for these pa-
tients the Dutch guidelines indicate embryo and oocyte cryopreservation as preferred method 
[53]. Before cancer treatment, patients receive a hormone treatment to stimulate the ovaries 
and harvest oocytes, which can either be cryopreserved as oocytes, or as embryos. The biggest 
disadvantage however, is that administration of adjuvant therapy has to be delayed.
Ovarian tissue cryopreservation can be performed immediately, making it the only avail-
able method for patients in which the start of adjuvant therapy cannot be delayed [54]. In 
short, one of the ovaries is laparoscopically removed, the cortex – outer portion of the ovary 
in which the oocytes reside – is cut into small fragments, which are frozen and stored in liquid 
nitrogen [55]. The cortex fragments can be thawed and transplanted back to the remaining 
1
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ovary or a peritoneal window after the completion of cancer treatment. It is still seen as an 
experimental technique, up to date ovarian tissue transplantation has been performed in 318 
women worldwide, and renewed ovarian endocrine function was reported in 95% of them [56]. 
One major concern however is the safety of the procedure: malignant cells might be present in 
the transplanted ovarian tissue, possibly reintroducing cancer. 
Current techniques used to examine the ovarian cortex fragments such as histology, poly-
merase chain reaction analysis and xenotransplantation are destructive [51]. This means, only 
few fragments can be tested for the presence of tumor cells, and those that are tested cannot 
be transplanted back. In this thesis we looked at the feasibility of FF-OCT – a non-destructive 
technique – to image ovarian cortex fragments.
Breast cancer
Breast cancer is the most common cancer type in women – with almost 15,000 new cases per 
year – and the second cause of cancer death in the Netherlands [35]. Around 60 to 75% of 
patients is treated with breast conserving therapy (BCT): surgically removing the tumor while 
leaving as much of the breast intact as possible followed by radiotherapy [57, 58]. Multiple 
studies have demonstrated that BCT is as effective as a mastectomy for the treatment of stages 
I and II invasive breast cancer when looking at local recurrence and overall survival [57, 59, 60]. 
However, it is important to remove all tumor tissue, as positive resection margins significantly 
increase the odds on local recurrence (pooled odds ratio of 2) [61].
A negative margin means that no tumor cells are found at the cut edge of the resected 
specimen. A positive resection margin, where tumor cells are found at the cut edge, means 
the patient either has to undergo a re-excision or an adjusted radiation therapy protocol, 
depending on the extensiveness of tumor on the margin [62]. To remove the whole tumor and 
achieve negative resection margins, surgeons rely, intraoperatively, mainly on visualization and 
palpation. Some surgical guidance techniques, such as wire-guided localization, intraoperative 
ultrasound (US) guidance, radio occult lesion localization, and radiolabeled seed localization 
have been developed to localize non-palpable lesions [63, 64]. Furthermore, pathological 
techniques to examine the margins intraoperatively, such as frozen section analysis and imprint 
cytology are extensively researched for the purpose of reducing the percentage of positive 
margins. However, all these methods have known drawbacks, such as time-consuming and 
resource-intensive nature, difficulty in visualizing high-grade carcinomas, and imprecision, due 
to sampling errors and poor resolution [65–69]: re-excision rates still lie around 20% [58, 61, 
70, 71]. These numbers emphasize the necessity for the development of new intraoperative 
margin assessment tools. In this thesis we looked at the use of FF-OCT to image breast tissue, 
and its feasibility to help pathologists to distinguish normal from tumor tissue.
16
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oUtLIne oF tHIs tHesIs
The central objective of this thesis is to study the feasibility of optical imaging techniques to 
differentiate tumor tissue from surrounding tissue. The main research question of this thesis: 
Is it feasible to differentiate tumor tissue from surrounding tissue using optical imaging 
techniques; and which technique can be of added value for clinicians in which clinical situation? 
Chapter 2, 3 and 4 focus on the use of full field optical coherence tomography for fertility 
preservation and margin detection in breast and pancreatic cancer. The fifth chapter of this 
thesis focusses on the use of single fiber reflectance spectroscopy to guide EUS-FNA proce-
dures of pancreatic lesions. In the last chapter, fluorescence lifetime measurements are used to 
distinguish bound from unbound tracer, with the ultimate goal to better detect margins during 
surgery.. (Table 1)
Table 1. Techniques and clinical applications used in this study. 
Full Field OCT SFR Spectroscopy Fluorescence lifetime
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Autotransplantation of ovarian tissue can be used to restore fertility in cancer patients follow-
ing gonadotoxic treatment. Whether this procedure is safe remains unclear, as current tumor 
detection methods render the ovarian tissue unsuitable for transplantation. Full-field optical 
coherence tomography (FF-OCT) is an imaging modality that rapidly produces high-resolution 
histology-like images without the need to fix, freeze, or stain the tissue. In this proof-of-concept 
study, we investigated whether FF-OCT can be used to detect metastases in ovarian tissue, 
thereby increasing the safety of ovarian tissue autotransplantation. We also evaluated whether 
cortical ovarian tissue and follicles remain viable following FF-OCT imaging.
Experimental design
Formalin-fixed, paraffin-embedded tissue samples were obtained from seven normal ovaries 
and fourteen ovaries containing metastases and/or micrometastases. These samples were de-
paraffinized and imaged using FF-OCT. The FF-OCT images were then compared to correspond-
ing hematoxylin-and-eosin-stained tissue sections. Finally, we examined the effect of FF-OCT 
imaging on the viability of ovarian tissues and follicles in fresh bovine ovarian tissue using a 
glucose uptake and neutral red staining, respectively.
Results
FF-OCT illustrated both normal structures and metastases in ovarian tissue within minutes. 
Primordial follicles were readily identifiable. Finally, tissues and follicles remained viable fol-
lowing FF-OCT imaging for up to 180 and 60 minutes, respectively.
Conclusion
FF-OCT imaging is a promising method for the non-invasive detection of metastases, including 
micrometastases, in ovarian tissue. Moreover, this method facilitates the selection of cortical 
ovarian tissue with the highest density of primordial follicles, potentially increasing the likeli-
hood of restoring ovarian function following ovarian tissue autotransplantation.
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IntRodUCtIon
Although advanced screening methods and novel treatment modalities represent a great 
leap forward in the treatment of cancer leading to substantially increased survival rates, new 
concerns have arisen as a consequence of these remedies, particularly among young women. 
Specifically, chemotherapy and/or pelvic radiotherapy can lead to premature ovarian failure 
due to accelerated follicle loss.[1] Therefore, preserving female reproductive capability is 
extremely important and has high priority. Currently, the most established fertility preserva-
tion procedures include freezing of embryos and/or oocytes. In addition, cryopreservation and 
subsequent autotransplantation of cortical ovarian tissue has become more prevalent. Because 
this method obviates the need for hormonal stimulation, it is deemed particularly suitable 
for prepubescent girls and young women who cannot delay the start of adjuvant therapy.[2] 
Autotransplantation of frozen-thawed ovarian tissue has been shown to restore ovarian activ-
ity in 93% of cases, and to date 60 resulting live births have been reported worldwide.[3-4] 
Despite these encouraging statistics, the safety of this procedure cannot yet be ascertained 
for certain types of cancer, as there is a potential risk of occult ovarian involvement at the 
time of tissue harvesting.[5-6] Due to the fact that the current tumor detection methods (e.g. 
histology, PCR analysis) render the tissue fragment unsuitable for transplantation, the presence 
of disseminated tumor cells can only be determined in the ovarian tissues that are ultimately 
not transplanted. Consequently, tumor cells that have metastasized to the actual ovarian auto-
grafts can be reimplanted, thereby potentially re-establishing cancer in the recipient. Previous 
reports have documented recurrences following autotransplantation in a patient diagnosed 
with breast cancer [7] and a patient diagnosed with cervical cancer.[8] However, whether these 
recurrences can be directly attributed to autotransplantation remains unclear. On the other 
hand, it is entirely plausible that malignant cells were reintroduced by autotransplantation in a 
patient with a granulosa cell tumor.[9]
To minimize the likelihood of reintroducing tumor cells, a technique that is capable of 
discriminating malignant from healthy tissues while leaving the examined tissues unaffected 
is needed. Full-field optical coherence tomography (FF-OCT) is a promising new imaging mo-
dality that satisfies these key criteria. Importantly, FF-OCT rapidly generates high-resolution 
histologylike images without the need to fix, freeze, or stain the tissue.[10] With FF-OCT, the 
image contrast is based on the light-scattering properties of different structures in the tissue. 
FF-OCT has already been used successfully to detect tumors in a wide variety of human tissues, 
including prostate,[11]skin,[12] brain,[13] lung,[14] and kidney[15] samples.
In this proof-of-concept study, we investigated whether FF-OCT can be used to visualize 
normal structures as well as metastases—including micrometastases—in human ovarian tis-
sue. In addition, we evaluated whether cortical ovarian tissue and preantral follicles remain 




Human ovarian tissue specimens
Formalin-fixed, paraffin-embedded (FFPE) specimens of normal ovaries obtained from pre-
menopausal women who underwent prophylactic bilateral oophorectomy because of the 
presence of a BRCA gene mutation in the period 2001-2012 were selected from the archives 
of the Department of Pathology at the Leiden University Medical Center (LUMC). Patients who 
were previously treated with chemotherapy or used oral contraceptives prior to oophorectomy 
were excluded in order to ensure that only functionally active ovaries were included in the 
study. In addition, via a nationwide search performed by PALGA, the Dutch histopathology and 
cytopathology network and archive that covers all pathology laboratories within the Nether-
lands,[16] FFPE specimens of ovarian metastases were collected from women with primary 
invasive breast cancer at age < 41 years in the period 2000-2010. Ovarian metastases derived 
from other primary malignancies in which ovarian tissue cryopreservation is performed were 
collected from the archives of the Department of Pathology at the LUMC. Hematoxylin-and-
eosin (H&E) stained tissue sections were obtained and digitized using an IntelliSite Pathology 
Ultra-Fast scanner 1.6 RA (Philips, Eindhoven, the Netherlands). Following this, the entire FFPE 
tissue blocks were deparaffinized and imaged using FF-OCT. 
All patient samples and clinical data were handled in accordance with the medical ethics 
guidelines described in the Code of Conduct for the Proper Secondary Use of Human Tissue of 
the Dutch Federation of Biomedical Scientific Societies (FMWV).[17]
Bovine ovarian tissue specimens
Intact bovine ovaries were collected at an abattoir within 15 minutes after slaughtering and 
immediately transported on ice to the laboratory at the LUMC. The average transport time was 
20 minutes. At the laboratory, each ovary was cut into two halves, and the medulla was re-
moved. The remaining cortex was trimmed to a thickness of 1-2 mm and subsequently cut into 
fragments measuring 2-3 mm or 5-10 mm in diameter for a glucose uptake assay or a neutral 
red staining, respectively. Bovine cortical ovarian fragments were stored until imaging (ranging 
from 0 to 180 minutes) in 24-wells plates at 4°C. Each well contained 1.5 ml DMEM culture 
medium (Lonza BioPharma; Visp, Switzerland) supplemented with 10% FCS (Gibco, Thermo-
Fisher; Waltham, MA) and 1% penicillin/streptomycin (MP Biomedicals; Santa Ana, CA).
Full-field optical coherence tomography
A commercially available LightCT FF-OCT system (LLTech; Paris, France) was initially used in 
thisstudy.[18] During the course of the study, the LightCT scanner was upgraded to a newly 
developed FF-OCT system (LLTech), which is faster and can accommodate larger tissue samples. 
Both systems consisted of an upright microscope with a 10x objective with a central wavelength 
of 700 nm with spectral width of 125 nm, and reference arm in the Linnik interferometric 
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configuration.[19-20] The light reflected by the tissue interferes with the light reflected by 
the reference mirror, and the signal is then isolated from the scattered background light using 
a combination of four phase shifted interferometric images. The LightCT scanner, which was 
used for the viability experiments, uses a 150-Watt white halogen lamp as the light source and 
generates a 0.8 mm x 0.8 mm en face image (with a maximum field of view 25 mm in diameter 
using image mosaicking) at an image rate of 35 Hz. The newly developed FF-OCT system, which 
was used to image the human ovarian tissues, uses an LED lamp as the light source and gener-
ates a 1.3 mm x 1.3 mm en face image (with a maximum field of view 45 mm in diameter) at 
an image rate of 75 Hz.
Image acquisition was similar for the two systems. In brief, the tissue was placed in the 
sample holder. Deparaffinized ovarian tissue was covered with saline, whereas fresh ovarian tis-
sue was covered with DMEM culture medium (Lonza BioPharma) supplemented with 10% FCS 
(Gibco, Thermo-Fisher) and 1% penicillin/streptomycin (MP Biomedicals). An optical window 
was positioned above the tissue, and the tissue was gently flattened against this window. A layer 
of silicone oil was then applied between the optical window and the microscope objective. A 
macroscopic image was obtained using a wide-field camera, followed by FF-OCT images, which 
were made en face. The field of view encompassed the entire cortical ovarian fragment. With 
respect to human ovarian tissues, images were taken at a depth of 0-20 μm to ensure the best 
possible correspondence with the histology images. Considering the bovine cortical ovarian 
fragments, images were taken up to a depth of 100 μm, as it was the maximum depth at which 
high resolution could be retained. The number of images taken in depth depended on the time 
that was needed to achieve the predefined imaging time for the viability tests (ranging from 
0 to 180 minutes). Both systems had 1.5 μm transverse resolution and 1 μm axial resolution.
Determining the viability of ovarian tissue using the glucose uptake assay
Bovine cortical ovarian tissue fragments measuring 2-3 mm in diameter were imaged using 
the LightCT scanner for 3, 10, 60, or 180 minutes. Fresh cortical ovarian samples that were 
not imaged served as a control, whereas cortical ovarian tissue samples in which cell death 
was induced by snap-freezing in liquid nitrogen served as a negative control. After imaging, 
the ovarian samples were transferred to 24-well plates for culturing. Each well was prepared 
in triplicate and contained three cortical ovarian samples in 1.5 ml DMEM culture medium 
(Lonza) supplemented with 10% FCS (Gibco, Thermo-Fisher) and 1% penicillin/streptomycin 
(MP Biomedicals). During culture, the medium was checked periodically for the presence of 
bacteria under a light microscope. The glucose content of the culture medium was measured 
using a blood-gas analyzer (Modular P Chemistry Analyzer; Roche Diagnostics, Indianapolis, IN). 
After four days in culture, the samples were weighed, and glucose consumption was measured 
and expressed per milligram of ovarian tissue per day, as previously described.[21-22]
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Determining the viability of ovarian follicles using neutral red staining
The viability of preantral ovarian follicles was determined using a neutral red staining assay 
adapted from the protocol published by Kristensen et al.[23] Fresh bovine cortical ovarian 
fragments were imaged in triplicate using the LightCT scanner for 3, 10, 60, or 180 minutes. 
These ovarian fragments were 5-10 mm in diameter and 1-2 mm thick. Fresh cortical ovarian 
fragments that were not imaged served as a control, and cortical ovarian tissue fragments in 
which cell death was induced by snap-freezing in liquid nitrogen served as a negative control. 
After imaging, the ovarian fragments were cut into small pieces. These pieces were placed in 
15-ml conical tubes containing 5 ml preheated Serum-free Ultraculture medium (Lonza) supple-
mented with 1 mg/ml collagenase type IA (Sigma-Aldrich, St. Louis, MO). During incubation, 
the cell suspensions were triturated through a 5-ml pipette to further disrupt the tissue. After 
incubation for 25 minutes at 37°C, the samples were centrifuged at 2500 rpm for 5 minutes. 
The supernatants were poured off, and each pellet of cells was incubated for 1.5 hours at 37°C 
in 4.8 ml McCoy’s medium (Life Technologies, Carlsbad, CA) supplemented with 2 μl Albuman 
(200 g/L; Sanquin, Amsterdam, the Netherlands), 50 μl Insulin-Transferrin-Selenium (ITS-G; Life 
Technologies), 50 μl penicillin/streptomycin (MP Biomedicals), and 75 μl neutral red solution 
(3.3 g/L; Sigma-Aldrich). The number of red-colored (viable) and uncolored (non-viable) fol-
licles in the partially dissolved ovarian tissue fragments were counted in ten high-power fields 
per specimen under a light microscope by two independent observers (I.P. and P.S.) who were 
blinded with respect to the samples.
Statistical analysis
Statistical analysis was performed using SPSS version 23.0 (IBM, Armonk, NY). Inter-observer 
agreement was calculated using the Pearson correlation coefficient. A multivariate linear 
regression model was used to compute the mean difference in the glucose uptake of cortical 
ovarian biopsies between the various FF-OCT exposure times. The values were adjusted for 
the number of ovaries included. To investigate the effect of FF-OCT imaging on the viability 
of preantral follicles, we compared the proportions of viable preantral follicles between the 
various FF-OCT exposure times.
ResULts
Human ovarian tissue specimens
FFPE tissue samples from seven normal ovaries (obtained from six premenopausal patients) 
and fourteen ovaries containing metastases and/or micrometastases (obtained from twelve 
patients) were deparaffinized and imaged using FF-OCT. In most cases, the FF-OCT images could 
be easily interpreted using the inverse setting. In this inverse setting, structures that reflect 
light the strongest appear black, whereas structures that reflect light poorly appear white. 
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Figure 1 shows representative FF-OCT images and corresponding histology images of the 
most clinically relevant structures in a normal ovary. The primordial follicles, which are small 
primary oocytes surrounded by a single layer of flattened granulosa cells,[24] appear as either 
round or crescent-shaped white structures, depending on the level at which they were imaged 
(Figure 1A-B). In primary follicles, the flat granulosa cells transform into a cuboidal structure and 
the zona pellucida forms between this layer and the oocyte. On the FF-OCT image, the oocyte 
appears somewhat darker than the zona pellucida, and the granulosa cells can be distinguished 
quite well (Figure 1C-D). Figure 1E-F shows a corpus rubrum, which is a small hemorrhage that 
forms immediately after ovulation. The corpus luteum is composed of an outer layer of smaller 
thecallutein cells and an inner layer of larger granulosal-lutein cells. On the FF-OCT images, the 
densely packed thecal-lutein cells reflected more light than the granulosal-lutein cells, which 
reflected light to the same extent as the corpus rubrum (Figure 1G-H). The corpus albicans 
(Figure 1I-J) and corpus fibrosum (Figure 1K-L), which are masses of fibrous scar tissues that 
form when the oocyte is not fertilized, showed high levels of reflection due to their collagen 
content. Lastly, an inclusion cyst (Figure 1M-N) was identified by its thin dark outer layer and 
lack of interior structure. 
Figure 2A shows representative FF-OCT images of a sagittal section of an ovary containing 
micrometastases; this sample was derived from a primary invasive ductal breast carcinoma. 
Figure 2B-C and Figure 2D-E show magnified views of micrometastases measuring 0.9 mm and 
1.7 mm, respectively. These metastatic lesions could be distinguished clearly from the sur-
rounding stromal cells, as the stromal cells reflected considerably more light than the lesions. 
On the FF-OCT images, these lesions have a ‘web-like’ architecture in which the tumor cells 
appear light gray. Furthermore, a distorted ovarian cortex architecture (Figure 2D) was often 
seen in the presence of disseminated tumor cells. Figure 3 shows metastatic lesions within 
ovarian tissues obtained from three individual patients. Figure 3A-B depicts a solitary metas-
tasis that originated from an invasive ductal breast carcinoma; the FF-OCT image shows the 
microglandular proliferation. In Figure 3CD, the ovarian stroma is completely occupied by the 
metastatic lesion, which has a characteristic stromal component. The FF-OCT image of a metas-
tasis originating from a primary endometrial carcinoma shows a typical cribriform morphology 
(Figure 3E), with good correspondence with the previously obtained H&E tissue section (Figure 
3F). The morphological features of the remaining ten ovaries containing metastatic disease 
corresponded to those depicted in Figures 2 and 3. All types of normal ovarian features and 




Figure 1. Example inverse FF-OCT images (left column) and corresponding histology images (right column) of normal ovarian 
tissues. The following normal ovarian structures are shown in the images: primordial follicles (A–B), a primary follicle (C–D), 
a corpus rubrum (E–F), part of a corpus luteum (G–H), a corpus albicans (I–J), a corpus fibrosum (K–L), and an inclusion cyst 
(M–N). In each image, the normal ovarian structures are indicated by an arrow. All but one primordial follicle were detected 
in the FF-OCT image (A) as compared with the corresponding histology image (B). This is due to a slightly different imaging 
depth. Scale bars, 100 mm (A and B), 150 mm (C and D), 250 mm (K–N), and 1 mm (E–J). Insets show a characteristic primor-
dial follicle (A–B) at three times higher magnification.
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Figure 2. Example inverse FF-OCT images and corresponding histology images of ovarian metastases originating from a pri-
mary invasive ductal breast carcinoma. A sagittal view is shown in A, and B to E show magnified views of the micrometastases 
(indicated by arrows); scale bars, 2 mm (A), 250 mm (B–C), and 500 mm (D–E).
Figure 3. Example inverse FF-OCT images (left column) and corresponding histology images (right column) of ovarian me-
tastases. An ovary containing a solitary metastasis originating from a primary invasive breast carcinoma is shown in A and B 
(indicated by arrows). An ovary in which disseminated breast tumor cells are dispersed throughout the ovary is shown in C 
and D. Micrometastases originating from a primary endometrial carcinoma are shown in E and F (indicated by arrows); scale 
bars, 500 (A–D) and 200 mm (E–F).
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Viability of ovarian tissue measured using a glucose uptake assay
Next, we examined whether performing FF-OCT imaging on fresh cortical ovarian tissue affects 
tissue viability. Table 1 shows the mean glucose consumption per mg ovarian tissue per day 
over a 4-day culture period of the fresh cortical ovarian tissues that were imaged using FF-OCT 
for 0, 3, 10, 60, and 180 minutes. All values were adjusted for the number of ovaries used, and 
none reached statistical significance. Thus, cortical ovarian tissue remained viable — at least 
with respect to glucose uptake — up to three hours of FF-OCT imaging. No glucose uptake was 
measured in the cortical ovarian biopsies in which cell death was induced.
Viability of preantral ovarian follicles measured using neutral red staining
We also examined the effect of different FF-OCT exposure times on the viability of preantral fol-
licles in fresh cortical ovarian tissue fragments using neutral red staining. The percentage of vi-
able preantral follicles in the samples that were not subjected to FF-OCT imaging was 86% (95% 
CI 0.81-0.92; Table 2). Although some variation was observed, this viability did not significantly 
decrease following FF-OCT imaging for up to 60 minutes. Cortical ovarian tissue fragments that 
were exposed to FF-OCT for 180 minutes had a significantly lower percentage (55%) of viable 
preantral follicles. As a negative control, no viable preantral follicles were observed in the corti-
cal ovarian tissues in which cell death was induced. Figure 4 shows representative examples 
of preantral follicles in fresh cortical ovarian tissues that were not exposed to FF-OCT imaging 
(Figure 4A), preantral follicles that were subjected to FF-OCT imaging for 10 minutes (maximum 
time required to image a cortical ovarian fragment; Figure 4B) and preantral follicles that were 
exposed to FF-OCT imaging for 180 minutes (Figure 4C).





0 min 50.52 (42.66-58.38)
3 min 46.49 (38.63-54.35)
10 min 44.25 (36.40-52.11)
60 min 40.32 (32.46-48.18)
180 min 46.25 (38.39-54.11)
 NOTE: The mean glucose uptake over a 4-day culture period was determined in triplicate, as described in the Materials and 
Methods section. All values were adjusted for the various ovaries, using a multivariate linear regression model, resulting in 
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dIsCUssIon
In this proof-of-concept study, we investigated whether FF-OCT can be used to detect metas-
tases in ovarian tissue prior to autotransplantation, thereby reducing the risk of reintroducing 
ovarian tissue that might contain metastases. We found that FF-OCT can be used to visualize 
both normal structures and metastases — including micrometastases — in ovarian tissues 
derived from premenopausal women. These findings are particularly relevant from a clinical 
perspective, given that the pathologist must distinguish between benign and malignant le-
sions based solely on tomographic images. Routine pathology methods such as histology and 
immunohistochemistry cannot be used in this context, as these methods render the cortical 
ovarian tissue unsuitable for autotransplantation. Importantly, our results may serve to help 
pathologists use FF-OCT as a novel tool for detecting metastases in ovarian tissues. 
In our study, we used deparaffinized FFPE tissue samples, as fresh ovarian tissues were not 
readily available for research purposes and ovarian metastases are relatively rarely encoun-
tered. However, we found no difference with respect to visual assessment of normal ovarian 
Table 2. Viability of preantral follicles after different FF-OCT exposure times
Total number of 
follicles observed




0 min 145 125 0.86 0.81-0.92
3 min 208 183 0.88 0.84-0.92
10 min 193 189 0.98 0.96-1.00
60 min 195 185 0.95 0.92-0.98
180 min 179 99 0.55 0.48-0.63
NOTE: The proportion of viable preantral follicles was determined by a neutral red staining. Results are based on three differ-
ent cortical ovarian fragments per condition.
aCI: confidence interval
Figure 4. Viability of preantral follicles before and after FF-OCT imaging. Representative images of preantral follicles in fresh 
cortical ovarian tissues that were not exposed to FF-OCT imaging are shown in A. Preantral follicles in cortical ovarian tissues 
that were subjected to FF-OCT imaging for 10 minutes are shown in B. Preantral follicles in cortical ovarian tissues that were 
subjected to FF-OCT imaging for 180 minutes are shown in C. The white and black arrows indicate red-colored (i.e., viable) 
and uncolored (i.e., non-viable) follicles, respectively; scale bars, 100 mm.
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structures between the deparaffinized ovarian tissue samples and the fresh ovarian tissues that 
were used for measuring viability. Our finding is supported by a study of Wilson et al. in which 
the optical features of various non-paraffinized and deparaffinized tissues were compared and 
no substantial differences were found.[25]
Because of the relatively few number of ovarian tissue samples that contained micrometas-
tases, we were unable to perform a blinded analysis in which two pathologists independently 
assessed the FF-OCT images without having access to the original H&E-stained tissue sections. 
Such an analysis would require a ‘training set’ in order to familiarize the pathologists with 
non-neoplastic and neoplastic ovarian tissues on FF-OCT, followed by a ‘test set’ for which the 
sensitivity and specificity of FF-OCT imaging could be determined.14-15 Although this type 
of analysis was beyond the scope of this proof-of-concept study, it should be performed in 
future studies in order to confirm whether FF-OCT is a suitable diagnostic instrument for use 
in ovarian tissue. 
The maximum depth of FF-OCT imaging that provided high-resolution images in the cortical 
ovarian strips was approximately 100 μm, which is considerably lower than the imaging depth 
of up to 500 μm reported for other tissues.10 This difference is due primarily to the large-
scale extracellular matrix network in the ovarian cortex,[26-27] which greatly reduces tissue 
penetration.[28] Nevertheless, imaging depth could be increased somewhat by imaging the 
cortical ovarian tissue fragments from both sides, thereby effectively doubling the amount of 
tissue that can be imaged. Moreover, rapid advances in the field of optical imaging will likely 
enable clinicians to use this non-invasive approach to visualize even deeper structures in the 
near future.
Interestingly, previous studies that used conventional OCT to examine ovaries achieved an 
imaging depth of up to 2 mm.[29-30] However, the imaging resolution of conventional OCT is 
considerably lower than FF-OCT.[31] For our purposes, achieving ultra-high resolution is crucial, 
as patients with clinically diagnosed early-stage cancer who are eligible for cryopreservation 
of ovarian tissue can potentially have occult micrometastases in their ovarian tissues.[32-34] 
Importantly, FF-OCT imaging provides images with a resolution of approximately 1 μm.31 In 
addition to the detection of occult ovarian involvement, this high-resolution imaging modality 
provides the opportunity to visually assess the density of primordial follicles in the ovarian 
autografts, which is highly relevant, given that successfully restoring ovarian activity depends 
critically on the number of primordial follicles present in the ovarian autograft.3 Thus, FF-OCT 
provides the added value of selecting the cortical ovarian fragments with the highest potential 
for restoring fertility.
Because FF-OCT generates images at a rapid rate,15 this technique is particularly suitable 
to the field of ovarian tissue cryopreservation, where ischemia and oxidative stress during a 
lengthy avascular period are known to cause loss of primordial follicles.[35] The average time 
required to image a cortical ovarian fragment measuring 5-10 mm in diameter was seven min-
utes using the original FF-OCT system, and this time was reduced further to a mere one minute 
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with the newly developed FF-OCT system. During these brief periods, the viability of both the 
ovarian tissue and the preantral follicles remained high. Even performing FF-OCT imaging for 
180 and 60 minutes did not significantly reduce the viability of ovarian tissues and preantral 
follicles, respectively. These data support the notion that short-term FF-OCT imaging has little 
effect on either ovarian tissues or preantral follicles. Nevertheless, given that the most mean-
ingful outcome in the field of fertility preservation is ultimately a successful pregnancy, future 
research will focus on evaluating pregnancy rates following exposure to FF-OCT.
With respect to using FF-OCT as a non-invasive means to detect metastases in the actual 
ovarian autografts, cortical ovarian strips can be imaged immediately following oophorectomy 
(see the proposed workflow diagram in Supplementary Figure 1). If the pathologist observes 
lesions that raise a suspicion of metastases, these fragments could then be analyzed further 
using histological examination and/or PCR analysis. If these further tests confirm the presence 
of metastatic tissue in the ovarian fragments, no autotransplantation will be performed. On the 
other hand, if the histological results are negative (i.e., a false positive result on FF-OCT), the 
remaining ovarian fragments—particularly those fragments that appeared normal on FF-OCT 
imaging—can still be transplanted. Moreover, as discussed above, the pathologist can also se-
lect the tissue fragments with the highest density of follicles, thereby maximizing the likelihood 
of restoring the patient’s ovarian function. Importantly, FF-OCT imaging should be performed 
under sterile conditions in order to prevent bacterial contamination.
In conclusion, FF-OCT imaging is a promising new non-invasive method for rapidly detecting 
ovarian metastases in ovarian fragments prior to autotransplantation in patients whose ovar-
ian function has been lost. Moreover, this method facilitates the selection of cortical ovarian 
tissues with the highest density of primordial follicles, significantly increasing the likelihood 
of restoring ovarian function. Although it is not yet possible to detect all ovarian metastases 
and/or follicles in the cortical ovarian fragments due to a limited tissue penetration depth, 
FF-OCT provides a large improvement over the current tumor detection methods as it is the 
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Supplementary fi gure 1 Proposed clinical workfl ow for screening corti cal ovarian strips prior to autotransplantati on in order 
to minimize the likelihood of reintroducing tumor cells and maximize the likelihood of restoring ovarian functi on. The light-
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Purpose: Over 20% of women undergoing breast conserving surgery require a re-excision, 
emphasizing the need for the development of new intraoperative margin assessment tools. 
Full-field optical coherence tomography (FF-OCT) is a non-invasive, high resolution imaging 
modality that could potentially help 
Methods: 100 images were collected from 44 patients who underwent breast surgery be-
cause of cancer. Two pathologists scored independently 77 images after a brief training. Results 
were compared to those obtained with standard hematoxylin and eosin (H&E) slides.
Results: Overall, pathologist 1 achieved a sensitivity, specificity and accuracy of 63%, 97% 
and 81% respectively. Pathologist 2 achieved a sensitivity, specificity and accuracy of 86%, 68% 
and 77% respectively. In 4 cases, both pathologists scored false-positive, the percentage of fat 
in these cases was significantly higher.  
Conclusion: FF-OCT images could be interpreted by pathologists. However, the current 
accuracy with which this is done, is not yet sufficient to be reliably used in clinical practice. We 
believe that with several measures – improved training, better contrast and computer aided 
diagnosis – accuracy can be increased. 
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IntRodUCtIon
Breast cancer is the most commonly diagnosed cancer and leading cause of cancer death in 
women 1. The preferred method of treatment for women with early stage breast cancer is 
breast conserving surgery (BCS) – removing the tumor without removing excess healthy breast 
tissue – followed by radiotherapy 2. In BCS, it is pivotal that borders of the excised specimen 
do not contain any tumor cells, since tumor-positive resection margins are associated with a 
higher risk of local recurrence 3–6. 
To remove all tumor cells and achieve negative resection margins, surgeons rely mainly 
on visualization and palpation during surgery. Over the years, several surgical guidance 
techniques were developed to localize non-palpable lesions, such as wire-guided localization, 
intraoperative ultrasound, radio occult lesion localization, and radiolabeled seed localization. 
Furthermore, pathological techniques to examine the margins intraoperatively, such as frozen 
section analysis and imprint cytology are studied for the purpose of reducing the percentage 
of positive margins in BCS 7. However, all these methods are limited by their drawbacks, most 
importantly, time-consuming and resource-intensive nature, difficulty in visualizing high-grade 
carcinomas, and imprecision, due to sampling errors and poor resolution 7–11. As a result, over 
20% of women undergoing BCS still require a re-excision 12–16, emphasizing the need for the 
development of new intraoperative margin assessment tools.
Optical imaging has the potential to improve intraoperative margin assessment as the tech-
nique enables non-invasive and real-time visualization of molecular and physiological changes 
associated with cancer. Numerous optical techniques, including diffuse reflectance spectros-
copy, intrinsic fluorescence spectroscopy, Raman spectroscopy, fluorescence lifetime imaging, 
radiofrequency spectroscopy, photoacoustic imaging and optical coherence tomography (OCT) 
are being investigated for this aim 17–22.
OCT was first described in 1991 and uses low-coherence interferometry to produce two-
dimensional cross-sectional images 23. It has been implemented in ophthalmology and cardiol-
ogy, and its added value in surgical oncology is being studied 24. Full-field OCT (FF-OCT) is a 
modality, based on the principles of white light interference microscopy, and acquires en face 
images by illuminating the whole field of view without scanning 25. It enables non-invasive, 
high-resolution imaging of thick fresh tissue without the need for tissue staining, coloring, fixat-
ing or slicing, by measuring the backscattered light of tissue structures with different refractive 
indices. 
In a pilot study, Assayag et al. used FF-OCT to image human breast tissue and evaluate 
whether these images had sufficient detail for a pathologist to make a diagnosis 26. In that 
study, images of 78 breast specimens of 21 patients, including both cancer and normal tissue, 
were assessed by two pathologists, achieving an accuracy of 83%. In this study we tried to rep-
licate those results using the same FF-OCT device within a broader patient cohort and added a 
46
Chapter 3
second-level interpretation (to differentiate normal, benign, in situ and invasive tissue), to add 
a more in depth diagnosis.  
MAteRIAL And MetHods
Patient and sample selection
Successive patients who underwent surgery for breast cancer at the Leiden University Medical 
Center were included in this study. From each patient, if achievable, one tissue section with and 
one tissue section without tumor was obtained. This selection was made based on macroscopic 
assessment by the pathologist. The fresh tissue sections were not fixated and non frozen. All 
patient samples and clinical data were handled in accordance with the medical ethic guidelines 
described in the Code of Conduct for the Proper Secondary Use of Human Tissue of the Dutch 
Federation of Biomedical Scientific Societies (FMWV) 27.
FF-OCT imaging and sample processing
Images were obtained using a commercially available high resolution FF-OCT system (Light-CT™ 
scanner, LLTech SAS, Paris, France). The setup consists of an upright microscope with a 10x 
objective, a halogen light-source with a wavelength of 700±125 nm, and a reference arm in 
Linnik interferometric configuration 28,29. The images are acquired at an image rate of 35 Hz, 
in a en face mode. Although the field of view is 0.8 by 0.8 mm, this can be increased by using 
image mosaicking (with a maximum diameter of 25 mm). Image resolution is 1.5 µm isotropic, 
and image depth is adjustable, with a maximum depth of several millimeters, depending on 
tissue properties 30. 
The tissue samples were placed in the sample holder, with the surface to be imaged facing 
upward, and covered in saline. An optical window was positioned on top of the tissue, to which 
the tissue was gently flattened. A layer of silicone oil was then applied between the optical 
window and the microscope objective. A macroscopic image was obtained using a wide-field 
CCD camera, followed by FF-OCT images. FF-OCT images were acquired at a depth of 20 µm, to 
ensure the best possible correspondence with histology images. Imaging time for one sample 
(on average 2.5 by 1.5 cm) was on average 30 minutes.
After FF-OCT imaging, tissue samples were formalin fixed and embedded in paraffin. 
Hematoxylin-and eosin-stained (H&E) slides were obtained and digitalized with a digital pathol-
ogy slide scanner (IntelliSite Ultra Fast Scanner, Philips, Eindhoven, the Netherlands). FF-OCT 
images were viewed using in-house developed analysis software based on MeVisLab (MeVis 
Medical Solutions AG and Fraunhofer MEVIS, Germany). 
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Assessment FF-OCT images
Two pathologists, one experienced in breast pathology (pathologist 1, TB), and one experienced 
in gastroenterology and liver pathology (pathologist 2, AF), participated in this study. An image 
atlas with representative FF-OCT images of normal breast and breast cancer tissues, together 
with their corresponding H&E images was constructed. Both pathologists followed a brief 
training, in which the atlas (including 10 images of normal, benign and malignant tissue) was 
shown, and the technique and method of tissue imaging were explained. The interpretation 
was performed on 77 images. The images were presented in random order to both pathologists 
although in the same order. The reading process of the FF-OCT images was standardized. All 
images were scored in the presence of one assessor (PLS), who completed the pre-designed 
reading sheet (Appendix 1) on basis of the pathologist’s assessment. Pathologists were allowed 
to digitally zoom the images, to adjust brightness and contrast, and to look at both the original 
and inverse setting FF-OCT image. In the original setting, hypo-scattering areas (such as adipose 
tissue) appear black in the image, while hyper-scattering areas (such as collagen) appear white. 
This is reversed in the inverse setting, making it more similar to H&E images. Clinical data in-
cluding macroscopic imaging, tumor localization or patient records were not presented to the 
pathologists during the study. 
In a first level interpretation, the pathologists classified the tissue slides as malignant or 
benign or unclassifiable. In a second level interpretation, the pathologists classified the tis-
sue slides as normal, benign, in situ carcinoma or invasive carcinoma. When both in situ and 
invasive carcinoma were present, concordance is only accomplished when the pathologist 
indicated invasiveness (the more severe diagnosis). Minor discrepancy was defined as in situ 
classification while being invasive carcinoma or the other way around. Major discrepancy was 
defined as a failed diagnosis or when benign is seen as normal tissue or the other way around. 
Statistical analysis 
The results of the individual region-of-interest scores were put in a 2x2 contingency table to 
calculate sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) 
and accuracy. 
Differences in time to reach a diagnosis were calculated using a t-test assuming unequal 
variances. Differences in fat percentage (scored by a pathologist based on H&E images) between 
correctly and incorrectly diagnosed malignant tissues were calculated using an ANOVA table.
ResULts
Patient and tissue description
A total of 107 tissue samples were collected from surgical specimens from 50 breast cancer pa-
tients. Part of those images were used for the training session. These images were not used as 
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test images. In total, 77 images of tissue samples collected from 44 patients were assessed by 
both pathologists. All patients underwent breast surgery, either lumpectomy or mastectomy. 
Patient and treatment characteristics are provided in Table 1. In total, 77 images with both 
histologic and FF-OCT diagnosis were present. On first-level interpretation, 36 were malignant 
and 41 were benign. On second-level interpretation, 35 were normal breast tissue, 6 were 
benign breast tissue, either benign lesions (fibroadenoma, myofibroblastoma, location of the 
tumor-marking clip or the place of a previous biopsy) or inflammation, 6 contained in situ car-
cinoma, 29 contained invasive carcinoma, and 1 contained both in situ as invasive carcinoma. 
Diagnostic test characteristics
Pathologist 1 classified 73 out of 77 FF-OCT images (95%), pathologist 2 classified 70 out of 
77 FF-OCT images (91%). The pathology assessment of the FF-OCT images in the first-level 
interpretation is provided in Table 2. Overall accuracy was 81% for pathologist 1, and 77% for 
pathologist 2. Pathologist 1 achieved a 63% sensitivity and 96% specificity, while pathologist 
2 achieved a 86% sensitivity and 68% specificity. Reading time ranged from 0.5 to 11 minutes 
and was on average 2.7 minutes for pathologist 1. Reading time ranged from 0.5 to 8 minutes 
Table 1. Patient and treatment characteristics
Characteristics N=44
Age (y), mean 55.8 (19-85)
Tumor size (mm), mean 21.8 (3-60)
Histological diagnosis, n (%)
IC NOS/DCI 25 (56)
   Grade I 6 (24)
   Grade II 6 (24)
   Grade III 8 (32)
ILC 5 (11)
   Grade I 2 (40)
   Grade II 2 (40)




Surgical procedure, n (%)
Lumpectomy + SN 16 (36)
Mastectomy 3 (7)
Ablation 18 (41)
Needle guided lumpectomy 4 (9)
Excision biopsy 3 (7)
Neoadjuvant therapy 11 (25)
3
49
Diagnostic accuracy of full-field optical coherence tomography in patients
and was on average 1.7 minutes for pathologist 2. Both pathologists had a significant higher 
average reading time when they misdiagnosed; for pathologist 1 this was 4.5 minutes versus 
2.3 minutes (p=0.02), for pathologist 2 this was 2.3 minutes versus 1.5 minutes (p=0.02). In the 
first half of the assessment both pathologists mostly used both the original and the inverted 
setting of the FF-OCT image to reach a conclusion. In the second half they mostly used the 
original setting of the FF-OCT images, and they reached a diagnosis faster. 
Benign FF-OCT images
In 14 out of the 41 benign FF-OCT images either one of the pathologists classified a benign 
image as a malignant one, none of the images were misclassified by both pathologists. In Figure 
1 examples of normal and benign tissue are provided. Normal breast tissue mainly consists of 
glandular tissue, adipose tissue, and dense and loose fibrous tissue. Glandular tissue can be 
recognized by structural characteristics, although they are not always as clear as they appear in 
H&E images as no cytonuclear details can be seen on FF-OCT. The adipose cells are very typical: 
large hypo-scattering cells which appear black, apart from their membranes. For the supporting 
fibrous tissue, a wavy architecture corresponds to the loose fibrous tissue. Fibroadenomas are 
well recognizable on FF-OCT images by the abundance, and size of epithelial tissue and large 
ducts. Only in 1 out of the 4 FF-OCT images of fibroadenomas one pathologist incorrectly clas-
sified it as a an invasive malignancy.
Table 2. Diagnostic test characteristics of FF-OCT on breast cancer specimens per pathologist
Pathologist 1 Pathologist 2 
Unclassified 4 7
True positive 22 31
True negative 37 23 
False positive 1 11
False negative 13 5
Total 77 77 
Sensitivity 63% 86% 
Specificity 97% 68% 




Figure 2 shows examples of both in situ carcinoma and invasive ductal carcinoma. Out of the 
77 FF-OCT images, 4 were misclassified by both pathologist. all of these were malignant and 
classified as benign. In two of these cases only some very subtle lobular in situ carcinoma was 
found on H&E examination (Figures 2E and 2F). In one case, a small nest of lymphovascular 
invasion (LVSI) was found and at the border a small nest of invasive tumor, while the remaining 
part existed of over 80% of adipose tissue. Upon reviewing this H&E image (which was done 
after reviewing the FF-OCT images), pathologist 1 already mentioned he would never be able 
to see this on the FF-OCT images. The last case (Figures 2I and 2L) both contained some in 
situ and invasive carcinoma, and was a grade II IC-NST. The FF-OCT image did not show the 
typical characteristics, such as a strong stromal reaction. Pathologist 1 did see a lot of epithelial 
structures, and hesitated to call it in situ, but eventually thought the size and amount was not 
abnormal. He thought it could be atrophic tissue in and older woman. 
The fat percentage demonstrated a relationship with diagnostic accuracy (Figure 4). Higher 
fat percentages in H&E images resulted in a significantly higher number of misdiagnosed cases 
(p<0.001). 
Figure 1. FF-OCT image of normal breast tissue (A), a fibroadenoma (B), and tissue in which the marker was positioned (C), all 
with their corresponding H&E images (D-F). Scale bars represent 2 mm.
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Figure 2. FF-OCT images of in situ carcinomas (A-C) and invasive ductal carcinomas (G-I), both with and without typical tumor 
features recognizable on FF-OCT images, with their corresponding H&E images (D-F, J-L). Some images contain the typical 
characteristics in abundance, while other only contain either one of them or in a very small amount, making it difficult for 
pathologist to identify. Scale bars represent 2 mm, except for 2H and K where scale bars represent 1 mm.
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Figure 3. FF-OCT images of an invasive lobular carcinoma (A and C), with their corresponding H&E images (B and D). Scale 
bars represent 2 mm. 
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Figure 4. Learning curves of both pathologists.




For the second-level interpretation, pathologist 1 deemed 60 out of 77 cases classifiable and 
pathologist 2 deemed 50 out of 77 cases classifiable. Table 3 provides their accuracy. In situ 
carcinoma was hardest to correctly diagnose; only 2 out of 11 (18%) second level interpreta-
tions (of both pathologists combined) indicated in situ carcinoma. Major discrepancies mostly 
were the same cases as the false positives and false negatives of the first level interpretation.
dIsCUssIon
In this study we investigated whether pathologists were able to distinguish malignant from 
benign breast tissue based on FF-OCT images. We found that pathologists 1 and 2 reached 
an accuracy of 81% and 77% respectively. Pathologist 1 was able to interpret the FF-OCT im-
ages with a very high specificity (97%), but low sensitivity (63%), while pathologist 2 reached 
a high sensitivity (86%), but low specificity (68%). Pathologist 2 was more afraid of missing 
malignancy, pathologist 1 only classified images as malignant when there was a very strong 
indication. The accuracy we reached is comparable with that of Assayag et al., who reached 
an accuracy of 83%. This however is not sufficient to eventually use the technique for margin 
detection in a clinical setting. We do believe that this could be achieved with some adjust-
ments: more extensive training, other contrast mechanisms, and computer aided diagnosis.
To train pathologists effectively, pathologists require direct correlation between H&E and 
FF-OCT images. However, acquiring FF-OCT images at exactly the same position as H&E coupes 
are taken, is challenging. We noticed that pathologists were often not very confident on their 
diagnosis. With more experience and direct feedback, we believe accuracy and confidence of 
interpretations will grow. This was already seen in the relative small dataset in this study: for 
both pathologists the learning curve increased (from 60% to 87% for pathologist 1 and from 
67% to 82% for pathologist 2). Thereby, other FF-OCT studies also showed an increased ac-
curacy in the assessment of images. In prostate biopsies, accuracy improved from 60% to 80% 
within one study 31, and was 93% in a later study 32.
Table 3. Correlation between actual diagnosis and second level interpretation for both pathologists com-

















Normal 39 2 4 7
Benign 1 7 3 -
In situ carcinoma - - 2 2
Invasive carcinoma 5 3 2 33
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Four cases were misdiagnosed by both pathologists, all of them false-positives. In three 
cases only a very small amount of in situ or invasive carcinoma was present, in one case it 
was a invasive lobular carcinoma grade I. Especially small amounts of tumor, are extremely 
difficult for pathologists to see in FF-OCT images, as a large part of the diagnosis is made using 
the architecture and stromal alignment. Images with a lot of fatty tissue, little stroma or only 
very small amounts of tumor are often mistaken for benign tissue. This was confirmed by our 
analysis: the amount of fat significantly correlated with the amount of incorrect interpretations. 
FF-OCT contrast is not sufficient to distinguish intracellular structures nor cytonuclear details. 
To increase accuracy of FF-OCT image interpretation, more detail is needed, for example to 
show cell nuclei. Currently, dynamic FF-OCT is being studied to provide enhanced detail, with 
promising results 33,34. Dynamic FF-OCT – also label free and non-invasive – visualizes metabolic 
activity at subcellular scale, by using the time dependence of the FF-OCT signal. Imaging can 
be performed with a similar setup used in this study, with a CMOS camera with an improved 
sensitivity. 
Thirdly, we think accuracy could be increased by taking advantage of computer aided 
diagnosis. In previous studies, automated detection algorithms of a-line OCT images were able 
to distinguish normal breast from tumor tissue with accuracies ranging from 81% to 92% 35–37. 
But also in large field images similar to FF-OCT images, automated detection has been proven 
effectively. Bredfield et al. 38, used tumor associated collagen signatures of breast cancer tissue 
to automatically detect the tissue type, reaching an overall accuracy of 91.9%. Focusing on 
collagen topography could even give additional information, as it is associated with a patients 
prognosis 39.
Finally, in this study, we did not provide clinical data to the pathologists, which is available 
to them in daily practice. This lack of information made interpretation even harder, as they 
normally do take this information into account in the interpretation of the histomorphology. 
Both pathologists deemed several images uninterpretable, that were excluded from further 
analysis. These were equally distributed over normal and tumor samples we believe that this 
exclusion does not represent a specific bias.
Several other groups have studied the use of OCT in breast cancer tissue, showing promis-
ing results. One recent study, by Ha et al. 40, achieved an average reader accuracy of 87% in 
assessing OCT images of breast specimens; readers included pathologists, radiologists and sur-
geons. Yao et al. 41, reached a 84% accuracy in assessing OCT images of breast specimens, using 
an automated classification algorithm. However, both studies suffered from a small dataset 
and excluded lobular carcinomas. Erickson-Bhatt et al. 42, used a hand-held OCT scanner to 
image resection beds in vivo in 35 patients undergoing surgery. Although accuracy rates varied 
from 58-88% between 5 readers and the study only contained few positive images, this study 
demonstrated the feasibility of real-time and label-free in vivo OCT imaging.
The desired clinical application is intraoperative imaging: looking at resection margins dur-
ing surgery to lower the re-excision rates for BCS. For this, the system used in this study is not 
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suitable; a handheld and faster device is necessary. Research into handheld OCT systems is 
extensive, and devices have become better in terms of resolution, speed, costs and size 43. Also, 
the first handheld FF-OCT prototype was already described 44, offering new perspectives for in 
vivo imaging. 
In this study we showed that pathologists could reach a combined accuracy of 79%. Al-
though this is not yet sufficient, we believe that the measures described above, could improve 
the accuracy, thereby making it feasible to introduce FF-OCT in the clinical practice.
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Appendix 1. Reading sheet
Reading sheet OCT beelden MAMMA        
          Datum: 
1. Algemene informatie 
Beoordelingsnummer: Beoordelaar 
Beeldnummer: Type beeld: positief/negatief/beide Tijdsduur: 
Beeldkwaliteit: slecht /matig/goed 
 
2. Herkenbare structuren 
Herkenbare normale structuren/type weefsels: 
 Vetweefsel   
 Stroma 





Stromal alignement:…………………………………………………………………………………………………………………………….  
Herkenbare pathologische structuren/type weefsels: 




 Fibroadenoom   
 Adenose 
 Necrose 
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Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United States. 
The minority of patients can undergo curative-intended surgical therapy due to progressive 
disease stage at time of diagnosis. Nonetheless, tumor involvement of surgical margins is seen 
in up to 70% of resections, being a strong negative prognostic factor. Realtime intraoperative 
imaging modalities may aid surgeons to obtain tumor-free resection margins. Full-field optical 
coherence tomography (FF-OCT) is a promising diagnostic tool using high-resolution white-light 
interference microscopy without tissue processing. Therefore, we composed an atlas of FF-OCT 
images of malignant and benign pancreatic tissue, and investigated the accuracy with which the 
pathologists could distinguish these.
Materials and methods
One hundred FF-OCT images were collected from specimens of 29 patients who underwent 
pancreatic resection for various indications between 2014 and 2016. One experienced gastroin-
testinal pathologist and one pathologist in training scored independently the FF-OCT images as 
malignant or benign blinded to the final pathology conclusion. Results were compared to those 
obtained with standard hematoxylin and eosin (H&E) slides.
Results
Overall, combined test characteristics of both pathologists showed a sensitivity of 72%, speci-
ficity of 74%, positive predictive value of 69%, negative predictive value of 79% and an overall 
accuracy of 73%. In the subset of pancreatic ductal adenocarcinoma patients, 97% of the FF-
OCT images (n = 35) were interpreted as tumor by at least one pathologist. Moreover, normal 
pancreatic tissue was recognised in all cases by at least one pathologist. However, atrophy and 
fibrosis, serous cystadenoma and neuroendocrine tumors were more often wrongly scored, in 
63%, 100% and 25% respectively.
Conclusion
FF-OCT could distinguish normal pancreatic tissue from pathologic pancreatic tissue in both 
processed as non-processed specimens using architectural features. The accuracy in pancreatic 
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IntRodUCtIon
Pancreatic cancer is the fourth leading cause of cancer related deaths with a 5-year survival rate 
of 8% in the United States [1]. Many patients present with locally advanced or metastasized 
disease and are beyond cure. Patients diagnosed with localized disease can undergo a poten-
tially curable treatment and have a 5-year survival rate around 20% [2±4]. Treatment consists 
of high-risk surgery (morbidity of 40±50% and mortality around 5% [5, 6]) usually followed 
or preceded by chemo(radio)therapy. During surgery, it is important to achieve a complete 
(R0) resection, as a distance of the tumor from the resection margin of _1 mm (R1 resection) 
is one of the most important prognosticators for poor survival in Europe [2, 7±9]. However, 
adequate intraoperative judgment is challenging, because the surgeon has to rely on visual 
inspection and palpation only. The presence of peritumoral inflammation in pancreatic cancer 
makes the distinction with normal tissue even more difficult. The incidence of R1 resections is 
up to 60±80% in published series of standardized pathological assessment [8±13], underlining 
the importance of adequate intraoperative resection margin assessment. 
Although various imaging modalities (such as CT, MRI, EUS and PET) are used to diagnose 
pancreatic cancer and assess its resectability prior to surgery, only few techniques are suitable 
during surgery [14]. Frozen section analysis is currently the most used intraoperative modality, 
especially to assess extra-pancreatic lesions [15]. However, it has low sensitivity (38%) evalu-
ating resection margins, and is therefore only used in selected cases at our institution [15]. 
Intraoperative ultrasound can be used to detect metastases or assess resectability, but its value 
in reducing positive resection margins is unknown, [14] and is the study object of an ongoing 
clinical trial at our institution. An emerging technique is near-infrared fluorescence imaging, 
which is based on a fluorescent tracer and dedicated cameras. Pre-clinical results demarcating 
pancreatic tumor are promising, but use tracers that are currently not yet FDA approved [16]. 
Thus, the current state-of-the art surgical approach encompasses high-risk intervention with 
limited success and little to no intraoperative visualisation of the malignant process. Novel 
intraoperative imaging tools are needed to improve the assessment of resectability and to 
guide subsequent resection. 
Optical coherence tomography (OCT) was first described in 1991 and uses low-coherence 
interferometry to produce 2-dimensional cross-sectional images [17]. It is already standard-of-
care in ophthalmology and cardiology, and with the development of new OCT modalities, other 
fields of interest – like oncology – are being discovered [18]. Full-field OCT (FF-OCT) is such 
a newly developed modality, based on the principles of white light interference microscopy, 
and acquires en face images by illuminating the whole field of view without scanning [19]. It 
enables non-invasive high-resolution imaging up to several millimetres of tissue without the 
need for tissue processing, by measuring the backscattered light of tissue structures with dif-
ferent refractive indices. Several studies report the use of FF-OCT in the field of oncology, i.e. 
on ovarian [20], skin [21] and brain tissue [22]. All showed encouraging results; architectural 
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changes could be identified, and in a quick fashion a large surface could be scanned. Only one 
study has been conducted in pancreatic cancer, but this was to evaluate fine needle aspirates 
[23]. FF-OCT has not yet been tested in pancreas resection specimens to discriminate malignant 
and benign tissues. 
In this feasibility study, we investigated whether pathologists were able to distinguish 
malignant from normal and benign pancreatic tissue based on FF-OCT images, obtained from 
surgical specimens.
MAteRIALs And MetHods
Patient and sample selection
Twenty-nine patients who underwent surgery for suspect pancreatic cancer at the Leiden Uni-
versity Medical Center (LUMC) were included in this study. Fresh tissue samples were collected 
prospectively (October 2015 until January 2016) from surgical specimens from 17 patients 
with (pre)malignant pancreatic lesions. Formalin-fixed paraffin embedded (FFPE) samples from 
12 patients were collected retrospectively (January 2014 until December 2014) from both 
benign and malignant pancreatic neoplasms to acquire FF-OCT images of different pancreatic 
neoplasms. No patients with a preoperative diagnosis of benign disease were included, for 
instance, patients with chronic or auto-immune pancreatitis were not included. From each of 
the 29 patients, if achievable, minimal one tissue section with presence of tumor and one 
tissue section without tumor were obtained. For the fresh samples, the selection was based 
on the macroscopic assessment by the pathologist; for FFPE samples, the selection was based 
on microscopic assessment. This resulted in 50 tissue samples (25 fresh samples and 25 FFPE 
samples). Per tissue sample, two regions of interest were selected by the study coordinator, 
LM, based on the corresponding H&E slides. These two regions of interest from a single tissue 
sections could be either both benign, both malignant or one malignant and one benign.
FFPE tissue blocks were deparaffinised, using a standard protocol. The study protocol was 
approved by the local medical ethics committee of the LUMC. The prospective collection of the 
fresh tissue samples was performed within the framework of routine clinical care. Therefore 
patient consent was not obtained, as this study was not subject to the Dutch Medical Research 
Involving Human Subjects Act, according to our local medical ethics committee. One author 
(LM) had access to patient information during clinical data acquisition after which patient data 
were anonymized. All patient samples and clinical data were handled in accordance with the 
medical ethics guidelines described in the Code of Conduct for the Proper Secondary Use of 
Human Tissue of the Dutch Federation of Biomedical Scientific Societies [24].
4
67
Validation of full-field optical coherence tomography in distinguishing 
FF-OCT imaging and sample processing
Images were obtained using a high resolution FF-OCT system (Light-CT™ scanner, LLTech SAS, 
Paris, France). In short, the setup consists of an upright microscope with a 10x objective, a halo-
gen light-source with wavelength of 700±125 nm, and a reference arm in Linnik interferometric 
configuration [25, 26]. It generates high resolution (1.5 μm isotropic), 0.8 by 0.8 mm en face 
images, but the field of view is increased using image mosaicking (with a maximum diameter of 
25 mm), at an image rate of 35 Hz. Image depth is adjustable, with a maximum depth of several 
millimeters, depending on tissue properties [27]. 
Tissue samples were placed in a sample holder in 0.9% NaCl solution with the surface 
to be imaged facing upward. A glass slide was positioned above the tissue to which it was 
gently flattened, and a layer of silicone oil was applied between the optical window and the 
microscope objective. A macroscopic image was obtained using a wide-field camera, followed 
by FF-OCT images. To ensure good correspondence with the histology images, FF-OCT images 
were acquired at a depth of around 20 μm. Imaging time for one sample was on average 30 
minutes. After FF-OCT imaging, tissue samples were formalin fixed and embedded in paraffin. 
H&E slides were obtained and digitalised with a digital pathology slide scanner (IntelliSite Ultra 
Fast Scanner, Philips, Eindhoven, the Netherlands). FF-OCT images were viewed using in-house 
developed analysis software based on MeVisLab (MeVis Medical Solutions AG and Fraunhofer 
MEVIS, Germany).
Study design
Two pathologists – one experienced and one resident – followed a brief training prior to assess-
ment of the FF-OCT images. The training was divided in two parts: in the first part the technique 
and method of tissue imaging were explained, and in the second part FF-OCT images were 
shown with their corresponding H&E images. The images of this training atlas were magnified 
regions of interest showing details of the different pancreatic tissues (such as normal pancreas, 
pancreatitis and pancreatic ductal adenocarcinoma (PDAC)); the whole slide was not presented 
to the pathologists. Moreover, the regions of interest used in the training atlas were different 
in the test cohort. 
The 100 regions of interest to be assessed by the pathologists were shown in the context of 
both the total FF-OCT image, and an enlarged (detail) image. They were offered to the patholo-
gists in both the original and inverse setting, as shown in Fig 1. During assessment pathologists 
were able to digitally zoom the images. FF-OCT images were randomly presented in the same 
order to the pathologists who were blinded to the H&E slides, patient information and final 
pathological diagnosis of the specimen. The pathologists had to classify the marked region-of-
interest as malignant or benign. If the pathologists found that the image quality was too poor 
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Statistical analysis
The results of the individual region-of-interest scores were put in a 2x2 contingency table to 
calculate sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) 
and accuracy for the complete cohort. In addition, diagnostic test characteristics and the 
interobserver variability were calculated after each cohort of 25 consecutive FF-OCT images. 
SPSS version 23 (IBM Corporation, Armonk, NY, USA) was used to calculate the interobserver 
variability and to compare the agreement in tumor identification by both pathologists, for 
which chi-squared tests were used. Kappa values were interpreted as described by Landis et 
Koch [28]. P<0.05 was considered statistical significant. Graphs were created using Graphpad 
version 7 (Graphpad Software, La Jolla, CA, USA).
ResULts
In FF-OCT images of normal pancreatic tissue, the morphologic features of major components 
could be identified, like interlobular septae, acinar tissue, islet cells, pancreatic ducts and blood 
vessels (Fig 2). Recognition of nerve bundles in normal pancreatic tissue was difficult (Fig 2). 
Interlobular septae are visible as light grey strands which are located between the lobuli. Islet 
cells were recognised as highlighted groups of cells located in acinar tissue. 
Histomorphology of pancreatic cancer in general and especially of PDAC is complex, being 
sometimes challenging to distinguish between malignant and reactive, benign glands in the 
context of pancreatitis even on H&E images [29]. On H&E images various criteria are used to 
Figure 2. Examples of FF-OCT images of normal pancreatic tissue and corresponding histology. Structures that are easily iden-
tified on FF-OCT images include normal pancreatic parenchyma (A-B), vessels (C-D), and a large pancreatic duct (E-F). Harder 
to recognize are nerve bundles (G-H). Scale bars, 250 μm (A-B, G-H), and 150 μm(C-F). Inset shows an islet of Langerhans (A-B) 
at 2.5 times higher magnification.
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distinguish between benign and malignant tissue. First of all, the pathologists look at low mag-
nification level to detect the presence of normal pancreatic architecture. Desmoplastic stroma, 
irregular ducts and disorganised glands are characteristics that indicate potential malignancy. 
Atypical cell nuclei, intraluminal necrosis, perineural invasion and ingrowth into structures as 
lymph nodes, blood vessels and fat tissue are all characteristics that point toward malignancy. 
If the lobular structure is maintained even in the presence of irregular ducts with some cyto-
nuclear atypia, pancreatitis should be considered. However, the difficulty resides in the fact 
that these essential features for the diagnostic on H&E slides are regularly not evaluable on 
the FF-OCT images. As shown in Table 1, only stroma and architectural distortion of pancreatic 
tissue and tumor glands are easily recognizable on FF-OCT images.
Scoring FF-OCT images
Fifty samples from 29 patients have been included in this study. Patient and tumor character-
istics are presented in Table 2. Of these tissue samples, 100 FF-OCT images were available for 
assessment: 57 benign and 43 malignant sections. The results of the FF-OCT assessment by 
the pathologists are detailed in Table 3 (and in S1 File). The more experienced gastrointestinal 
pathologist scored 6 images as not interpretable, the pathologist in training none. Of these 6 
images± 3 fresh and 3 deparaffinised FFPE± 3 were benign and 3 were malignant. These images 
were scored by the pathologist in training; 3 images were scored correctly, and 3 images were 
scored incorrectly. Leaving these 6 images out of the analysis, the experienced pathologist 
achieved a higher accuracy than the less experienced pathologist: 80% versus 67%, respectively. 
The combined results showed the following test characteristics: sensitivity of 72%, specificity of 
74%, PPV of 67%, NPV of 79% and an accuracy of 73%. 
Table 1. Comparison of features of pancreatic ductal adenocarcinoma detectable on H_E and on FF-OCT im-
ages.
Features of malignancy Detectable on H&Ea Detectable on FF-OCT
Disorganisation of lobuli and glands + +
Presence of atypical glands + ±b
Atypical cell nuclei + -
Presence of tumor stroma ± +
Ingrowth into structures (a.o. lymph 
nodes, blood vessels, fat)
+ ±
Intraluminal necrosis + ±
Perineural invasion + ±
a Adapted from Hruban et al. [28], these diagnostic characteristics are used in assessment of H&E images.
b Large atypical glands could be detected, but smaller glands are less visible and sometimes mistaken  for blood vessels. 
4
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Table 2. Patient and tumor characteristics
Characteristics
Age, mean (y) 65.7
Sex, n (%)
  Male 13 (45)
  Female 16 (55)
ASA score, n (%)
  1 5 (17)
  2 19 (66)
  ≥3 5 (17)
Tumor size (mm), mean 33.2
Tumor location, n (%)
  Pancreatic head 13 (45)
  Pancreas body/tail 10 (35)
  Distal CBD 1 (3)
  Peri-ampullar 5 (17)
Histological diagnosis, n (%)
  Adenocarcinoma 23 (79)
    Well differentiated 3 
    Moderately differentiated 10
    Poorly differentiated 7 
    Unknowna 3
  IPMN 1 (3)
  MCN 2 (7)
  NET 2 (7)
  Serous cystadenoma 1 (3)
Surgical procedure, n (%)
  PPPD 17 (59)
  Whipple 1 (3)
  Distal pancreatectomy 9 (31)
  Central pancreatectomy 1 (3)
  Total pancreatectomy 1 (3)
a Differentiation grade could not be determined in 3 cases, because of pancreatic fibrosis after neoadjuvant (chemo)radio-
therapy.
Abbreviations:
ASA: American Society of Anesthesiologists; CBD: Common bile duct; PPPD: Pylorus-preserving pancreaticoduodenectomy; 
IPMN: Intraductal papillary mucinous neoplasm; MCN: Mucinous cystic neoplasm; NET: Neuroendocrine tumor
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A more detailed overview of the scores per histologic type is provided in Table 4. Normal 
pancreatic parenchyma was correctly recognised by both pathologists in 32 of the 40 cases. 
Atrophy and fibrosis (Fig 3) were wrongly scored by both pathologists in 63%, serous cystad-
enoma in 100% and neuroendocrine tumors in 25% of the cases. Pathologists evaluated 35 
FF-OCT images of a PDAC (Fig 4), of which 34 were correctly scored as malignant by at least 
one pathologist. Well (grade 1) and moderately (grade 2) differentiated PDAC were scored 
as malignant by both pathologists in 67% and 57% of cases, respectively (Table 4). Whereas, 
poorly differentiated (grade 3) PDAC was scored as malignant by both pathologist in 1 out of 8 
cases (13%).
Table 3. Test characteristics of FF-OCT on pancreatic tissue. True positives are FF-OCT images which were 
correctly identified as malignant. True negatives are FF-OCT images which were correctly identified as benign. 
False positives are FF-OCT images which were incorrectly identified as malignant. False negatives are FF-OCT 
images which were incorrectly identified as benign. Pathologist 1 is the experienced pathologist, pathologist 












1 28 47 8 11 6 72% 85% 80%
2 30 37 21 12 0 71% 64% 67%
Overall
(mean)
29 42 15 12 3 72% 74% 73%
Table 4. Accuracy per histological diagnosis 
Correctly identified by 
both pathologists




   Normal pancreatic 
parenchyma
32 8 0
   Pancreatitis 1 2 0
   Atrophy or fibrosis 1 2 5
   Serous cystadenoma 0 0 2




   Grade 1 NET 0 1 1
   Grade 2 NET 1 1 0
   Grade 1 PDAC 4 2 0
   Grade 2 PDAC 12 8 1
   Grade 3 PDAC 1 7 0
   Malignant IPMN 1
Totala 54 31 9
a 6 images were scored as not interpretable by one of the pathologists, these are excluded from this analysis.
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Figure 3. Example of benign pancreatic tissue FF-OCT images and corresponding histology. Fibrotic pancreatic tissue after 
neoadjuvant therapy (A-B), pancreatitis (C-D), and a serous cystadenoma (E-F); scale bars all 500 µm.
Figure 4. Example FF-OCT image of a well differentiated pancreatic ductal adenocarcinoma. A shows a n overview. B shows a 
magnified view of stromal disorganization, and C shows nests of tumor cells. Scale bars, 2 mm (A), 1 mm (B), and 500 μm (C).
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The first 50 FF-OCT images given to the pathologists were taken from deparaffinised FFPE 
pancreatic tissue specimens, whereas the others were taken from fresh specimens. Univariate 
analysis showed no significant difference (P = 0.24) in evaluating fresh or deparaffinised FFPE 
FF-OCT images, however, fresh FF-OCT images appear to provide a more detailed view and 
improved visualization of tumor stroma. 
Interobserver variability
The overall interobserver variability (Kappa) was calculated and there was a fair agreement be-
tween the pathologists (Kappa: 0,33). After presentation of each set of 25 consecutive FF-OCT 
images the interobserver variability was measured and an increase of 0.1 to 0.5 was observed, 
as shown in Fig 5.
dIsCUssIon
In this study we investigated whether pathologists were able to distinguish malignant from 
benign pancreatic tissue based on FF-OCT images. We found that normal, healthy pancreatic 
tissue could be distinguished from malignant tissue very well due to the characteristic archi-
tecture of normal pancreatic parenchyma. Distinguishing other benign tissue types like chronic 
pancreatitis was harder. We also found that the experienced pathologist was better in assessing 
the FF-OCT images than the pathologist in training. To our knowledge this is the first study 
to evaluate the correlation between H&E slides and FF-OCT in detecting malignancies in fix-
ated and fresh pancreatic resection specimens. The diagnostic accuracy of 73% obtained in 
this study is not yet adequate, but we believe this can be improved upon by taking several 
measures: using other contrast mechanisms, improving knowledge on collagen topology, and 
more extensive training.
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Pancreatic pathology and in particular morphological differentiation between pancreatic 
ductal adenocarcinoma and pancreatitis is challenging even on H&E. On FF-OCT this differentia-
tion is difficult as well; although FF-OCT provides high resolution, the endogenous contrast is 
not proficient to see cell nuclei. Techniques to reveal subcellular metabolic contrast are being 
developed, showing encouraging results [30]. Other contrast mechanisms can provide addi-
tional information and thereby increase diagnostic accuracy.
Secondly, improved knowledge on the collagen topology could increase the diagnostic ac-
curacy. As collagen reflects light very well, tumor stroma is evidently visible on FF-OCT images. 
The pathologists mostly evaluated the FF-OCT images based on these architectural features. 
However in this study, both pathologists often misdiagnosed pancreatic atrophy and fibrosis as 
malignant. In these cases the presence of collagen fibers dominating the image could be mis-
taken for tumor stroma as PDAC is characterized by extensive and disorganized desmoplastic 
stroma [31]. Recently it was shown that its collagen topology differs significantly from that of 
pancreatitis [32]. Improved knowledge on the collagen topology of these benign conditions, 
and possibilities to detect these differences and correlation between stromal alignment and 
organization, and diagnosis, could increase the diagnostic accuracy. This feature could also be 
exploited in the future by automated detection of collagen characteristics, as was previously 
done for second harmonic generation images of breast cancer [33]. 
Our study consisted of two parts: 50 image regions of deparaffinised tissue and 50 image 
regions of fresh tissue shown to the pathologists in that order. In tissue imaged both fresh and 
deparaffinised we see that the intensity of collagen is higher in fresh tissue (S1 Fig). We did 
not find significant differences in the assessment between these parts. However, an increase 
in accuracy was shown for both pathologists in the second half (images 26±50 and 76±100) of 
each part, suggesting a learning curve. Another study on FF-OCT where they looked at prostate 
biopsies showed an overall accuracy of 70%, with a learning curve from 60% to 80% after evalu-
ation of 119 images; this is concordant with our data [34]. A later study on FF-OCT images of 
prostate core biopsies showed, after extensive training an overall accuracy of 93%. This implies 
that for pancreatic tissues further improvement is possible [35], therefore we believe that more 
training could further improve the diagnostic accuracy. We made a flowchart for assessment of 
pancreatic FF-OCT images which could support pathologists, although it should be validated in 
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Finally, we did not provide any clinical data to the pathologists. This lack of clinical informa-
tion made interpretation even more difficult as compared to daily practice when such informa-
tion is available and taken into account in the interpretation of the histomorphology.
We have not imaged resection margins of the surgical specimens as that would have af-
fected the clinical workflow too much, however, we included fresh pancreatic tissue for imaging 
to mimic the future application of intraoperative use. Moreover, we selected interesting and 
clinically relevant locations on the H&E and the corresponding FF-OCT images; for example, 
transition zones of infiltrating tumor glands and surrounding tissue (S2 Fig). Furthermore, to 
achieve an R0 resection margin in Europe, imaging up to 1 mm is necessary. In this study, we 
imaged at a depth of 20 μm to ensure good correspondence with reference H&E. As resolution 
decreases with increasing imaging depth, future studies should analyze the influence on ac-
curacy with increased imaging depth.
The more experienced pathologist did not find the imaging quality good enough to give 
a diagnosis in six cases that were excluded from further analysis. These images were equally 
distributed between the different groups (malignant, benign, fresh, deparaffinised) we believe 
that this exclusion does not represent a specific bias. 
Several other groups tried to identify pancreatic tumor tissue in order to reduce the amount 
of positive margins during surgery using various techniques. Hu et al. [36] used nonlinear optical 
microscopy to image pancreatic tumor xenografts harvested at different stages. They also saw 
an increased density of the collagen fibers in tumor compared with normal tissue. However, 
they did not do a blind reading of the images. Eberlin et al. [37], used mass spectrometry 
imaging and an automatic classifier to distinguish normal from cancer human pancreas tissue. 
They obtained a high agreement with pathology, but excluded cellular compositions that were 
not accounted for in their classifier, such as inflammation and necrosis, which is in contrast 
with our study, which included a broad spectrum of benign areas of disease to mimic clinical 
scenarios. Also our group studied the use of fluorescence-guided surgery during pancreatic 
resections. However, in human studies the results have been disappointing so far, as no useful 
tumor demarcation could be visualized with non-specific contrast agents [38, 39]. Currently, 
studies using tumor-specific fluorescent contrast agents are ongoing (Trial ID:NTR5673) [40]. 
Resection margins can either be examined in vivo before and during resection and after 
resection in the resection bed, or ex vivo on the resected specimen. Erickson-Bhatt et al. [41], 
used a portable OCT system to image the resection bed after a wide local excision of breast 
cancer. Tao et al. [42], also looked at resection margins in breast cancer, but examined ex 
vivo frozen sections using nonlinear microscopy, reaching an accuracy of 94.1%. We envision 
that FF-OCT could eventually be used during surgery at clinically suspect resection margins to 
further improve radical resection rates by extending the resection margin to facilitate en bloc 
tumor removal or by resecting additional tissue after suggestion of residual disease. 
The FF-OCT device used in this study is not yet applicable in surgery. For translation into 
the operating room for in vivo imaging a handheld and faster device is necessary; for ex vivo 
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assessment of resected specimens a bench top system is sufficient. Progression is made on 
both accounts. The first handheld endomicroscope based on FF-OCT was recently described by 
Benoit a la Guillaume et al. [43], which opens new perspectives for in vivo imaging. Further-
more, a 7 times faster and 3 times more sensitive camera was introduced in the device, also 
bringing it closer to clinical implementation [44].
In conclusion, FF-OCT could distinguish normal pancreatic tissue from pathologic pancreatic 
tissue, however, further development of the FF-OCT device and more experience in evaluat-
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Endoscopic ultrasound-guided fine needle aspirations (EUS-FNA) of pancreatic masses suffer 
from sample errors and low-negative predictive values. Fiber-optic spectroscopy in the visible 
to near-infrared wavelength spectrum can noninvasively extract physiological parameters 
from tissue and has the potential to guide the sampling process and reduce sample errors. 
We assessed the feasibility of single fiber (SF) reflectance spectroscopy measurements during 
EUS-FNA of pancreatic masses and its ability to distinguish benign from malignant pancreatic 
tissue. A single optical fiber was placed inside a 19-gauge biopsy needle during EUS-FNA and at 
least three reflectance measurements were taken prior to FNA. Spectroscopy measurements 
did not cause any related adverse events and prolonged procedure time with ∼5  min. An ac-
curate correlation between spectroscopy measurements and cytology could be made in nine 
patients (three benign and six malignant). The oxygen saturation and bilirubin concentration 
were significantly higher in benign tissue compared with malignant tissue (55% versus 21%, 
p=0.038; 166  μmol/L versus 17  μmol/L, p=0.039, respectively). To conclude, incorporation 
of SF spectroscopy during EUS-FNA was feasible, safe, and relatively quick to perform. The 
optical properties of benign and malignant pancreatic tissue are different, implying that SF 
spectroscopy can potentially guide the FNA sampling. 
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IntRodUCtIon
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is increasingly used as a di-
agnostic modality to obtain a cytological diagnosis of suspect pancreatic masses. Surgery is 
currently the only treatment option for long-term survival in patients with pancreatic cancer. 
However, only a small minority of patients is eligible for surgery due to late detection, and it 
is often performed without pathological confirmation of the diagnosis.1 Neoadjuvant therapy 
gains more interest to downsize the primary tumor and treat micrometastatic disease prior to 
resection.2 Consequently, the need for a pathological confirmation is warranted before the start 
of chemotherapy.3,4 Although EUS-FNA is a relatively safe procedure with a high specificity, it 
suffers from a high sampling error, resulting in a low-negative predictive value, and the need 
for an on-site cytopathologist.5,6 Moreover, the accuracy of EUS-FNA drops considerably when 
(peritumoral) pancreatitis is present, which most frequently occurs.7
Several techniques have been investigated to enhance the diagnostic accuracy including 
contrast enhancement, confocal laser endomicroscopy, and optical coherence tomography.8–12 
However, these techniques involve administration of a contrast agent or extensive training to 
interpret the images. Fiber-optic spectroscopy is a relatively novel diagnostic modality that 
already showed its feasibility in a pilot study to characterize pancreatic tissue and to differenti-
ate between normal and malignant tissue during surgery.13 Although these first in vivo results 
were encouraging, the size of the probe was not compatible with the small lumen of an FNA 
needle. No studies have yet been performed to assess the feasibility of fiber-optic spectroscopy 
during pancreatic EUS-FNA procedures.
Reflectance spectroscopy provides information about tissue absorption and scattering 
parameters. Light in the visible to near-infrared wavelength range is dominantly absorbed in 
the biological tissue by oxygenated and deoxygenated hemoglobin. Light is also absorbed by 
other chromophores, such as bilirubin and beta-carotene, depending on the tissue type. Single 
fiber (SF) reflectance spectroscopy uses only an SF to both emit the outgoing and capture the 
returning light. The advantage of using an SF is its ability to fit through an endoscopic biopsy 
needle, which, combined with its small sampling depth of approximately the fiber diameter,14 
allows measurements at the exact biopsy location. Using a priori knowledge of the absorption 
spectra of the chromophores, a previously developed, described, and validated mathematical 
model can be used to extract and quantify physiological information, such as tissue oxygenation 
and blood volume fraction, from the obtained spectra.14,15 In previous studies, our group has 
shown the potential of SF reflectance spectroscopy in detecting abnormal mediastinal lymph 
nodes during EUS-FNA procedures in patients with a clinical suspicion of lung cancer.16
In this study, we evaluated the feasibility of the incorporation of SF reflectance spec-
troscopy into pancreatic EUS-FNA procedures. The primary objectives were to assess the 
safety—assessed through adverse events—and ease of use—assessed through additional 
time taken—during the procedure. Moreover, we measured wavelength-dependent optical 
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characteristics of pancreatic masses and assessed whether we could distinguish benign from 
malignant pancreatic tissue based on their optical properties.
MAteRIAL And MetHods
Patients
This trial was approved by the Medical Ethics Committee of the Leiden University Medical 
Center and was performed in accordance with the ethical standards of the Helsinki Declaration 
of 1975. Sixteen patients planned to undergo an EUS-FNA procedure to obtain a diagnosis of a 
pancreatic mass were included. All patients provided informed consent and were anonymized. 
The EUS-FNA procedures were performed by two experienced gastroenterologists.
Measurement Setup
The experimental setup used in this study has been described in detail previously15 and is shown 
in Fig.1. In short, the setup utilizes a single optical fiber connected to a quadfurcated optical 
fiber. Two arms are connected; one arm leading from a halogen light source HL-2000-FHSA 
(Ocean Optics, the Netherlands), and a second arm leading to a spectrophotometer SD-2000 
(Ocean Optics, the Netherlands) to measure white light reflectance. A calibration procedure 
was performed to account for internal reflections, variability in lamp-specific output and in 
fiber-specific transmission properties.17
Sterilized single-use fibers (Leoni, Germany) had a core diameter of 300 μm, an outer diam-
eter of 700 μm, an SMA905 connector, a distal polished fiber for wide-angle beam, a numerical 
aperture of 0.22, and a length of 3 m (±0.2 m). The sampling depth depends on the optical 
properties but is typically similar to the core diameter of the fiber.14
Figure 1. Measurement setup. (a) The measurement device with laptop. The white arrow points at the connection point for 
the fiber. (b) The optical fiber, with a length of 3 m and an outer diameter of 700 μm. (c) Incorporation of the optical fiber 
into 19-G puncture needle.
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Examination Procedure
The procedure was performed using a curved linear array echo endoscope EG-327UK Slim, 
EG-3870UTK (Pentax Europe GmbH, Hamburg, Germany) or EG-580UT (Fujifilm, Tokyo, Japan). 
Patients were positioned in left lateral decubitus position under conscious sedation (50 mcg 
fentanyl, 3 mg midazolam) or deep sedation (propofol, administered by nurse anesthesist). 
After visualization of the pancreatic mass, the stylet of a 19-G biopsy needle (ECHO-19; Cook 
Medical, Bloomington) was replaced by a sterilized single-use fiber, after which the needle was 
placed into the endoscope channel and advanced into the target lesion. The fiber was extended 
a few millimeters through the biopsy needle to enable measurements without influence of 
the needle shaft. At least three reflectance measurements were acquired before FNA. At the 
time of these measurements, systemic blood saturation was measured using a pulse oximeter. 
Individual reflectance spectroscopy measurements were averaged over 10 measurements 
with an integration time of 100 ms. After obtaining spectroscopy measurements, the fiber was 
removed and the routine procedure was continued. The cytology slides with the resulting FNA 
were marked to correlate spectroscopy measurements to cytology outcome. The puncture was 
repeated a maximum of 5 times until the on-site cytopathologist had confirmed the adequacy 
of the sample. Spectroscopy measurements were only taken prior to the first puncture.
Pathologic Assessment of Cytology
The aspirated material was examined on-site to judge the sample for its adequacy. Punction 
material was expelled from the needle onto the glass slides and gently smeared. Air-dried 
smears were stained using the rapid RAL staining (RAL Diagnostics, Martical, France). Remaining 
material was formalin fixed; this material gives opportunity of performing ancillary techniques. 
After the procedure, all slides were examined by an experienced cytopathologist.
Mathematical Analysis of Spectra
SF reflectance spectra were analyzed using an analytical model to describe the wavelength-
dependent optical properties to extract physiological and morphological information from the 
sampled tissue. Previously, a similar model has been described for analysis of other tissues.18 
Attenuation due to absorption within the tissue is modeled using a modified Beer–Lambert law 
and is a function of both the tissue absorption coefficient (μa) and the SF photon path length. 
The reflectance amplitude, as well as the SF photon path length, depend on the scattering 
properties of the tissue, with a dependence on the reduced scattering coefficient (μ′s) and 
on the angular distribution of scattering (phase function), modeled through phase function 
parameter γ=(1−g2)/(1−g1) with g1 and g2 the first and second moments of the phase function, 
respectively. The dependence of the SF reflectance signal on phase function parameter gamma 
results from the overlapping source–detector areas utilized in SF measurements, for which the 




where dfib is the fiber core diameter and NA is the numerical aperture of the fiber (0.3 
mm and 0.22, respectively) and ηmedium is the refractive index of the pancreatic tissue under 
investigation, assumed to be 1.38.20 The reduced scattering coefficient was fitted as a power-
law function,17 μ′s=a0(λ/λ0)a1. Gamma was assumed to be constant over the fitted wavelength 
range, γ = a2. Furthermore, instead of fitting γ as a free parameter, we have also fitted Eq.(1) 
keeping γ fixed at 1.4, 1.6, and 1.8, which is an expected range for γ in biological tissues.21 
We have verified that these different approaches for fitting the data to Eq.(1) did not result in 
differences in the estimated absorption coefficient of more than 6%.
Since we have not previously performed measurements on pancreatic tissue, our initial 
model assumed that absorption was attributable to oxygenated (HbO2) and deoxygenated 
hemoglobin (Hb) confined within the local microvasculature and bilirubin according to the 
following equation:
where a3 is the blood volume fraction, a4 is the microvascular hemoglobin oxygen satura-
tion, Cv is a factor that accounts for the effect of discrete blood vessels on the absorption coef-
ficient and enables an estimation of the average blood vessel diameter dv=a6, a5 is the bilirubin 
concentration, μaBIL is the specific absorption coefficient of bilirubin, and μaHbO2 and μaHb are the 
specific absorption coefficients of oxy- and deoxyhemoglobin, respectively.
A Levenberg–Marquardt algorithm was used to estimate the parameter values a1−a6 by 
minimizing the chi-squared metric between measured reflectance data and model predictions. 
Confidence intervals on parameter estimates were calculated from the square root of the 
diagonal of the covariance matrix.22 Parameter values were averaged over repeated measure-
ments, weighted by the confidence interval of individual spectral fits, and reported with the 
associated weighted standard deviation.
In this study, spectra that showed evidence of a blood pool within the detection volume 
were identified by blood volume fraction a3>40% and excluded from the analysis as was done 
previously.18
Mathematical Analysis of Spectra 
SF reflectance spectra were analyzed using an analytical model to describe the wavelength-
dependent optical properties to extract physiological and morphological information from the 
sampled tissue. Previously, a similar model has been described for analysis of other tissues.18 
Attenuation due to absorption within the tissue is modeled using a modified Beer–Lambert law 
and is a function of both the tissue absorption coefficient (μa) and the SF photon path length. 
The reflectance amplitude, as well as the SF photon path length, depend on the scattering 
properties of the tissue, with a dependence on the reduced scattering coefficient (μ′s) and on the 
angular distribution of scattering (phase function), modeled through phase function parameter 
γ=(1−g2)/(1−g1) with g1 and g2 the first and second moments of the phase function, 
respectively. The dependence of the SF reflectance signal on phase function parameter gamma 
results from the overlapping source–detector areas utilized in SF measurements, for which the 
diffusion approxima ion does not hold.19 The complete model used to fit the data is given in the 
following equation: 
 
where dfib is the fiber core diameter and NA is the numerical aperture of the fiber (0.3 mm and 
0.22, respectively) and ηmedium is the refractive index of the pancreatic tissue under 
investigation, assumed to be 1.38.20 The reduced scattering coefficient was fitted as a power-
law function,17 μ′s=a0(λ/λ0)a1. Gamma was assumed to be constant over the fitted wavelength 
range, γ=a2. Furthermore, instead of fitting γ as a free parameter, we have also fitted Eq. (1) 
keeping γ fixed at 1.4, 1.6, and 1.8, which is an expected range for γ in biological tissues.21 We 
have verified that these different approaches for fitting the data to Eq. (1) did not result in 
differences in the estimated absorption coefficient of more than 6%. 
Since we have not previously performed measurements on pancreatic tissue, our initial model 
assumed that absorption was attributable to oxygenated (HbO2) and deoxygenated hemoglobin 
(Hb) confined within the local microvasculature and bilirubin according to the following 
equation: 
 
where a3 is the blood volume fraction, a4 is the microvascular hemoglobin oxygen saturation, 
Cv is a factor that accounts for the effect of discrete blood vessels on the absorption coefficient 
and enables an estimation of the average blood vessel diameter dv=a6, a5 is the bilirubin 
concentration, μBILa is the specific absorption coefficient of bilirubin, and μHbO2a and μHba 
are the specific absorption coefficients of oxy- and deoxyhemoglobin, respectively. 
Ma hematical Analysis of Sp ctra 
SF reflectance spectra were analyzed using an analytical model to describe the wavelength-
dependent optical properties to extract physiological and morphological information from the 
sampled tissue. Previously, a similar model has been described for analysis of other tissues.18 
Attenuation due to absorption within the tissue is modeled using a modified Beer–Lambert law 
and is a function of both the tissue absorption coefficient (μa) and the SF photon path length. 
The reflectance amplitude, as well as the SF photon path length, depend on the scattering 
properties of the tissue, with a dependence on the reduced scattering coefficient (μ′s) and on the 
angular distribution of scattering (phase function), modeled through phase function parameter 
γ=(1−g2)/(1−g1) with g1 and g2 the first and second moments of the phase function, 
respectively. The dependence of the SF reflectance signal on phase function parameter gamma 
results from the overlapping source–detector areas utilized in SF measurements, for which the 
diffusion approximation does not hold.19 The complete model used to fit the data is given in the 
following equation: 
 
where dfib is the fiber core diameter and NA is the numerical aperture of the fiber (0.3 mm and 
0.22, respective y) and ηmedium is the refractive index of the pancreatic tissue u der 
investigation, assumed to be 1.38.20 The reduced scattering coefficient was fitted as a power-
law function,17 μ′s=a0(λ/λ0)a1. Gam a was assu ed to be constant over the fitted wavelength 
range, γ=a2. Furthermore, instead of fitting γ as a free parameter, we have also fitted Eq. (1) 
keeping γ fixed at 1.4, 1.6, and 1.8, w ich is an expected range for γ in biological tissues.21 We 
have verified that these different approaches for fitting the data to Eq. (1) did not result in 
differences in the estimated absorption coefficient of more than 6%. 
Since we have not previously performed measurements on pancreatic tissue, our initial model 
assumed that absorption was attributable to oxygenated (HbO2) and deoxygenated hemoglobin 
(Hb) confined within the local microvasculature and bilirubin according to the following 
equation: 
 
where a3 is the blood volume fraction, a4 is the microvascular hemoglobin oxygen saturation, 
Cv is a factor that accounts for the effect of discrete blood vessels on the absorption coefficient 
and enables an estimation of the average blood vessel diameter dv=a6, a5 is the bilirubin 
concentration, μBILa is the specific absorption coefficient of bilirubin, and μHbO2a and μHba 
are the specific absorption coefficients of oxy- and deoxyhemoglobin, respectively. 
5
91
Toward optical guidance during endoscopic ultrasound-guided fine needle aspirations of pancreatic
Statistical Analysis
The statistical analysis and the graphs were generated using SPSS statistical software (Version 
22.0, Chicago, Illinois). Statistical analysis was carried out using the Kruskal–Wallis test on the 
parameters obtained from the fit. This test replaces data by rank and is considered adequate 
when data does not show a Gaussian distribution.23
ResULts
Patients
Sixteen patients undergoing a pancreatic EUS-guided FNA were included. In three patients no 
FNA, and thus no spectroscopic measurements, was performed, due to lack of visualization of 
the pancreatic mass. In the remaining thirteen patients, we were able to perform spectroscopic 
measurements. Of these, two patients were excluded due to a poor connection between the 
sterile measurement fiber and the quadfurcated optical fiber causing erroneous spectra and 
two patients were excluded due to lack of precise correlation with pathology (Fig.2). In the lat-
ter two patients, the yield of the 19-G needle biopsies was inadequate and instead, good qual-
ity FNAs were acquired with the more flexible and smaller 25-G needle. One of the excluded 
patients was a patient with a pancreatic neuroendocrine tumor; the final puncture, obtained 
with a 25-G needle, was performed at the same location where the 19-G needle was positioned 
and spectroscopy measurements were taken. Because the cytology correlation might not be 
completely reliable, we described SF reflectance spectra of this patient separately. Characteris-
tics of these patients are listed in Table 1.
Cytological results could be correlated with spectroscopy measurements in the remain-
ing nine patients, with cytological diagnosis of the spectroscopy-related FNA sample showing 
malignancy in six patients and benign disease in three patients. Two out of the three patients 
whose cytology showed a benign anomaly were at the end of their treatment plan suspect 
to suffer from pancreatic cancer. Patient #7 diagnosed with fibrotic inflammation, underwent 
pancreatic surgery based on clinical symptoms and preoperative images. The surgery was 
aborted due to hemodynamic instability. Patient #16, diagnosed with fibrosis, showed an in-
crease in tumor volume and thickened lymph nodes on a CT-scan, performed one month after 
the EUS-FNA. Both patients died within four months after the EUS-FNA procedure. Although 




Single Fiber Reflectance Spectra
No adverse events related to the spectroscopy measurements were observed. Additional 
endoscopy time related to the spectroscopic measurements was approximately five minutes.
Representative SF reflectance spectra from measurements taken at a benign and malignant 
spot (patients #16 and #2) are displayed in Fig. 3. In Table 2, the measured values of blood 
oxygen saturation, blood volume, and bilirubin concentration are displayed. Pancreatic tissue 
does not show much hemoglobin absorption features in the spectra, which are typically visible 
as “dips” in reflectance between 500 and 600 nm. The lack of strong absorption features in the 
spectra is reflected in the fitted values for the blood volume, which are low for both benign and 
malignant sites (1.1% and 2.2%, respectively; Fig. 4). The microvascular saturation is signifi-





3 excluded due to lack of FNA
2 excluded due to lack of cytology match
16 Patients
2 excluded due to calibration errors
Figure 2. Inclusion scheme of patients
Table 1 Patient characteristics. Patients 3, 6, and 12 were included, but no biopsy was taken so no SF reflec-
tance spectroscopy measurements were performed.
Patient Gender Age Site Diameter 
tumor (mm)
Cytology
1 M 71 Corpus 30 Malignant: mucinous cystic tumor
2 M 74 Corpus/tail 80 Malignant: adenocarcinoma
4a F 47 Head NS Neuroendocrine tumor
5 F 54 Head NS Malignant: metastasis 
adenocarcinoma ovary
7 F 70 Whole pancreas 50 Benign: fibrotic inflammation
8 a M 47 Head 25 Malignant: highly dysplastic cells
9 a M 63 Head and tail NS Benign: autoimmune pancreatitis
10 F 55 Tail 40 Malignant: adenocarcinoma
11 M 60 Corpus 33 Benign: autoimmune pancreatitis
13 F 60 Processus uncinatus NS Malignant: adenocarcinoma
14 F 53 Processus uncinatus 24 Malignant: adenocarcinoma
15 a M 69 Head/ Processus uncinatus 44 Benign: fibrosis
16 M 74 Head 20 Benign: fibrosis
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absorbs light mostly between 400 and 500 nm, with a peak around 450 nm. Benign sites were 
associated with significantly higher bilirubin content than malignant sites (166 μmol/L versus 
17 μmol/L, p = 0.039; Fig. 4). The amplitude and slope of the reduced scattering coefficient 
(a0 and a1, respectively) were not significantly different between benign and malignant tissue. 
Measurements of the patient who suffered from a pancreatic neuroendocrine tumor showed a 
blood level of 33.6% ± 1.6% with a saturation of 86.2% ± 12.1%.
Figure 3. Fitted spectra with corresponding cytology. (a) and (c) Spectra of a benign and malignant sample, respectively. The 
red line in the spectra indicates the actual measurements, and the black line shows the fit. The dotted line represents the 
expected spectra if no absorbers would be present in the sample. The residual—difference between measurement and fit—is 
shown below the spectra. (b) The corresponding cytology sample of (a): the lower left corner shows fibrosis (low magnifica-
tion). (d) The corresponding cytology samples of (c): pancreatic ductal adenocarcinoma cells are shown in the middle (high 
magnification).
Table 2. Extracted means and standard deviations of blood volume, saturation, and bilirubin per patient. 
Patient Cytology Blood volume (%) Saturation (%) Bilirubin (µmol/L)
result Mean sd Mean sd Mean sd
1 Malignant 0.7 0.3 29.4 45.9 2.5 1.8
2 Malignant 0.9 0.5 20.9 5.0 7.2 2.7
5 Malignant 1.4 0.4 0.0 7.8 11.8 3.1
7 Benign 0.3 0.1 48.3 30.3 39.2 18.1
10 Malignant 5.1 4.1 0.0 50.0 3.4 2.4
11 Benign 0.8 0.3 50.8 42.4 338.8 239.7
13 Malignant 3.1 1.9 49.6 4.2 26.6 0.5
14 Malignant 1.8 0.2 28.7 8.9 48.6 3.2





In this study, we showed that the incorporati on of SF spectroscopic measurements during 
EUS-FNA procedures of the pancreas is feasible and safe. Because the fi ber can be preloaded, 
measurements can be performed relati vely easily and quickly. In our pilot study, the endoscopic 
procedure was prolonged with ∼5 min on average, which could be shortened aft er gaining more 
experience. No adverse events related to the spectroscopy measurements were observed, 
making it a safe procedure. Moreover, we demonstrated that opti cal properti es, extracted from 
the SF refl ectance spectra, appeared to be diff erent between benign and malignant pancreati c 
aspirati ons. Therefore, incorporati on of fi ber-opti c spectroscopy could potenti ally help to guide 
the FNA procedures and thereby reduce the sampling error and increase its negati ve predicti ve 
value without signifi cantly aff ecti ng the complexity or ti me of the procedure.
Although EUS-FNA currently has a high specifi city, it suff ers from a low-negati ve predicti ve 
value implying that a negati ve result cannot be relied upon.24 This is also confi rmed by the 
current study: cytology results of three out of the nine pati ents showed a benign conditi on. Two 
out of these three pati ents (fi broti c infl ammati on and fi brosis), eventually turned out to have 
a malignancy by follow-up treatment or diagnosis and the FNA results thus represent sample 
errors. As more att enti on is given to neoadjuvant chemotherapy,2 which requires a pathological 
diagnosis, it is highly important to reduce the sampling error and increase the negati ve predic-
ti ve value of EUS-FNA procedures.
Pancreati c ductal adenocarcinoma is a hypovascular and a hypoxic tumor.25–27 This is con-
fi rmed in this study, since both the benign and malignant sites showed very low levels of mean 
blood volume (1.1% and 2.1%, respecti vely). These results are supported by a study of Erkan 
et al.,25 in which the microvascular density was determined: normal pancreas showed a fi ve 
ti mes higher microvascular density than fi broti c areas of chronic pancreati ti s, and four ti mes 
higher than pancreati c ductal adenocarcinoma. Interesti ngly, one of the pati ents in which we 
took measurements (but lacked good cytological correlati on) was diagnosed with a pancreati c 
Figure 4. Diff erence in blood volume, saturati on, and bilirubin concentrati on between cytological confi rmed benign and 
malignant sites. Every individual pati ent is indicated by a dot. P-values are displayed above the scatt erplots.
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neuroendocrine tumor, which are known to be hypervascular.28 That measurement indeed 
showed a far higher blood level of 33.6% ± 1.6% with a saturation of 86.2% ± 12.1%.
The saturation of hemoglobin is a marker for the level of hypoxia.29,30 We found significant 
lower mean saturation values in malignant areas compared to benign areas (21% and 55%, 
respectively), despite high overall arterial oxygen saturation values (>97%). This is in agreement 
with results of Koong et al.,31 who intraoperatively measured pancreatic tissue oxygenation (us-
ing an Eppendorf pO2 histograph) and found significant tumor hypoxia, whereas normal tissue 
showed normal oxygenation. In another study, patients undergoing pancreatic surgery received 
pimonidazole—a hypoxia tracer that can be detected in tissue by immunohistochemistry—and 
showed that more hypoxia was present in the epithelial regions than in the stromal regions of 
the tumor (although there was a high intra- and intertumoral heterogeneity) and the absence 
of hypoxia in adjacent normal pancreatic tissue.32 Additionally, Lohse et al.33 measured hypoxia 
in the stromal compartment of patient-derived pancreatic xenografts. They concluded that 
the levels of hypoxia in the tumor-associated stroma were generally lower when compared 
to the tumor compartment. These studies support our results. Although we did not measure 
normal tissue, we did—most likely—measure stromal areas of pancreatic adenocarcinoma 
in the two patients who suffered from fibrosis and inflammation (according to the cytology 
results obtained through EUS-FNA). These patients indeed showed a higher saturation and 
thus lower hypoxia levels than epithelial pancreatic adenocarcinoma regions. Furthermore, 
hypoxia is a known biomarker and potential therapeutic target in pancreatic cancer34–36 and in 
vivo saturation measurements could provide interesting additional information to increase our 
understanding of the role of hypoxia before and during neoadjuvant treatment.
The levels of bilirubin found in this study are within the range that could be expected for this 
patient cohort. However, we cannot directly correlate the bilirubin concentration measured in 
pancreatic tissue to the bilirubin concentration measured in plasma, since we are only optically 
sampling a small amount of tissue with a low blood volume fraction. Moreover, we did not 
prospectively measure serum bilirubin levels prior to EUS-FNA. This would be a valuable addi-
tion as bilirubin levels can change quickly in cholestatic patients. It is interesting to speculate on 
the reason for our observation of lower bilirubin levels in malignant tissue compared to benign 
tissue. This may be a consequence of the (isolated) tumor microenvironment characterized 
by low blood volume, combined with the reduced availability of heme in rapidly proliferating 
tumor cells37 and the possible degradation of bilirubin, known to be a strong antioxidant38 in 
tumor cells under oxidative and (inflammatory) stress.
One other clinical study described in vivo spectroscopy measurements in human pancreatic 
tissue.13 It was concluded that a difference between normal and malignant tissue could be 
observed in collected reflectance at wavelengths around 470 and 650 nm, measured with a 
multifiber probe. However, the diameter of the multifiber probe is too large to fit through an 
endoscopic biopsy needle, making a translation to standard EUS-FNA procedures difficult.
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Chapter 5
In this study, reflectance spectra were analyzed using a fit algorithm [Eq. (1)] that incor-
porates the fact that the reflectance amplitude and the SF photon path length depend on the 
scattering properties of the tissue, with a dependence on not just the reduced scattering coef-
ficient (μ′s) but also on the angular distribution of scattering (phase function) modeled through 
phase function parameter γ. We note that the use of Eq. (1) to fit the data no longer requires 
the use of the method described in a study by Kanick et al.39 In that study, instead of explicitly 
expressing the γ dependence of the collected SF reflectance, a set of empirical constants was 
used that minimized the error between the true and fitted SF path lengths. However, since the 
combined effects of μa, μ′s, and γ on SF reflectance are now fully captured by Eq. (1), such an 
approach based on empirical constants is no longer necessary for accurate estimation of μa. The 
fact that the different methods of fitting to Eq. (1) did not result in differences in the estimated 
μa of more than 6% indicates that this new method of fitting is robust.
A limitation of our study is the overall small sample size and small number of benign tis-
sue measurements. However, our primary aim was to study the feasibility of incorporating SF 
reflectance spectroscopy measurements into the EUS-FNA procedure. Although it is encourag-
ing that even with a small sample size differences in optical properties are observed, a larger 
(multicenter) study, including a wide variety of pancreatic lesions, is needed to fully exploit 
the potential of SF spectroscopy to guide the EUS-FNA sampling. In this study, we grouped 
pancreatitis with fibrous tumor parts (that were regarded as benign by the cytologist) together. 
More samples would enable us to also study the differences between these individual groups. 
The group of Hoffman et al., developed an orthotopic human tumor graft mouse model in 
which different fluorescent proteins were tested to image tumor progression.40,41 This approach 
could be interesting as it allows visual distinction between pancreatic cancer cells and the sur-
rounding stroma.42,43 In addition, several clinical trials are currently investigating the safety and 
feasibility of intraoperative near-infrared fluorescence imaging using pancreatic cancer-specific 
contrast agents (NTR5673, NCT02736578).
The fiber used in this study fits through a 19-G needle, but is too thick for the more flexible 
22-G needle, which is currently the preferred size at our gastroenterology department. Further-
more, we noticed that the SMA-connector of the sterile fiber was not always easily connected 
to the quadfurcated fiber, causing erroneous reflections in two patients. Future studies will, 
therefore, be performed with a smaller diameter fiber that fits through a 22-G needle, and with 
tighter tolerance requirements on the SMA-connector to secure a tight connection between 
fiber and measurement setup.
Real-time feedback is crucial to guide the gastroenterologist to epithelial tumor regions dur-
ing the procedure, and, since our spectral fitting method is sufficiently fast (<1s), this is feasible. 
Finally, to make the incorporation of SF reflectance spectroscopy into the FNA procedure even 
more simple, the small SF could potentially be integrated into the shaft of the biopsy needle, as 
already shown in a 15-G needle.44 Integration of the optic fiber would allow direct visualization 
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of the difference between benign and malignant tissue per patient, as we currently do not have 
data on intrapatient differences.
In conclusion, incorporation of SF reflectance spectroscopy measurements in EUS-FNA pro-
cedures of the pancreas is feasible and safe. Moreover, the optical properties differ between 
benign and malignant tissue sites, which could be used for real-time guidance of FNA sampling 
to reduce the sample error of these procedures and improve overall performance.
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Fluorescence lifetime measurements may increase the specificity of intraoperative tumor 
identification. We measured in vitro and in vivo fluorescence lifetimes of two cRGD-based fluo-
rophores – cRGD-ICG and cRGD-ZW800-1 – and investigated the ability to differentiate between 
their bound, tumor-specific, and unbound, aspecific, state.
In vitro, U87MG glioblastoma cells were incubated with different concentrations of either 
cRGD-ICG or cRGD-ZW800-1. In vivo, mice with subcutaneous U87MG tumors were adminis-
tered with either cRGD-ICG or cRGD-ZW800-1 along with a subcutaneous bolus in the tail. A 
time-domain single photon avalanche diode based system was used to measure fluorescence 
lifetimes of tumor and tail at 1-, and 24 hours.
In vitro, for cRGD-ICG no significant differences in lifetimes were measured between the 
concentrations, or between the different groups. In vivo, lifetimes of cRGD-ICG at the tumor 
were longer than those at the tail after both 1 hour (p<0.001), and 24 hours (p=0.022). Lifetimes 
of cRGD-ZW800-1 at the tumor were shorter than those at the tail after both 1 hour (p<0.001), 
and 24 hours (p=0.036). Histology confirmed bound and unbound states of the fluorescent 
dyes. 
The results showed that bound fluorescence probe exhibits a different lifetime compared 
to unbound fluorescence probe, indicating that in vivo lifetime measurements could potentially 
be used in addition to fluorescence guided surgery, to improve its specificity.
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IntRodUCtIon
Next to techniques that provide anatomical information such as MRI and CT, pre-operative 
imaging techniques, such as single-photon emission computed tomography (SPECT) and posi-
tron emission tomography (PET), increasingly aid oncologic surgeons in staging patients and 
planning their surgical procedure.1–3 Besides the incidental use of ultrasound, during surgery 
surgeons mainly rely on their hands and eyes with which it is challenging to discriminate be-
tween malignant and healthy tissues, potentially leading to inadequate resection margins and 
damage to (complex) vital structures.4,5
The recently introduced tumor-specific fluorescence-guided surgery (FGS) technique – using 
fluorescence intensity of exogenous contrast agents – can aid surgeons in identifying malignant 
tissues during surgery.4 Similar to SPECT/PET, FGS is based on molecular imaging, combining 
fluorophores with tumor-specific ligands. However, FGS shows higher spatial resolutions and 
provides real-time intraoperative feedback. The sensitivity and specificity of FGS depend on 
the tumor-to-background ratio (TBR) of the fluorescent signal: the ratio between the amount of 
signal in the tumor and that in the background. For sufficient TBRs, there always is a wash-out 
time of unbound agents, which can be as high as 72 hours for antibodies, and down to hours for 
smaller peptide-based agents.6,7 Generally, a TBR of two or higher is considered sufficient.8 Due 
to the inability of FGS to differentiate between specific (target bound) and aspecific (not target 
bound) tracer signals, and the lag-time between injection and optimal imaging time-points, 
it can be difficult to recognize clear margins and acquire adequate signals. No adjustment of 
the injected dose of the agent can be performed during operation. For example, when during 
surgery signals are too weak, no secondary dose can be administered as the optimal time-point 
is often hours till days later. Therefore, complementary techniques must be developed that 
can be used in parallel to FGS and deal with these demerits, like the analysis of fluorescence 
lifetime.
The lifetime of a fluorophore – the time a molecule resides in the excited state before 
returning to the ground state through fluorescence emission – is influenced by its physiological 
environment.9,10 In contrast to fluorescence intensity imaging, fluorescence lifetime imaging 
is generally insensitive to differences in concentration.11,12 To measure fluorescence lifetimes, 
which are typically in the order of nanoseconds, dedicated equipment is necessary. 
Several preclinical studies reported successful in vivo lifetime imaging of exogenous contrast 
agents for different applications.13–16 Biffi et al., conjugated rituximab (a monoclonal antibody) 
with Cy5.5 targeting CD20 antigen that is expressed on B-cell lymphoid malignancies. They 
reported higher lifetimes at the tumor than at the surrounding normal tissue.13 Ardeshipour 
and colleagues used fluorescence lifetime to study the efficacy of HER2 targeted therapy for 
breast cancer. They conjugated Alexafluor 750 to a HER2-specific Affibody and found that this 
probe showed a lower lifetime when bound to HER2 compared with unbound probe.14 Naka-
jima et al., showed the feasibility of detecting peritoneal ovarian tumors with Rhodamine green 
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using lifetime measurements, and observed that fluorescence intensity can be compromised 
by blood contamination whereas these lesions could still be detected by their fluorescence 
lifetimes.16 Although providing promising results, none of these used fluorophores that can be 
translated into human studies.
Clinically, the fluorophores methylene blue (MB) and indocyanine green (ICG) laid the 
foundation for FGS and are at present the only two near infrared (NIR) fluorescent dyes ap-
proved for off-label clinical use.17 More dedicated NIR fluorescent dyes, such as IRDye800CW 
and ZW800-1, were subsequently developed and are currently manufactured following cGMP 
guidelines and showed no toxicity or adverse events in animal toxicity studies and first-in-
human studies.18–22
Conjugating these NIR fluorescent dyes to tumor recognizing vehicles enables highly dis-
tinctive imaging. The amino acid sequence arginine-glycine-aspartate (RGD) is such a vehicle: 
it is a natural occurring peptide that recognizes at least 8 different integrins (αvβ1, αVβ3, αvβ5, 
αvβ6, αvβ8, α5β1, α8β1 and αIIbβ3) that are upregulated in various tumor types, and overexpressed 
on angiogenic endothelial cells within the tumor stroma.23,24 The high affinity for either the 
cancer cells, the supporting endothelial cells, or both cell types together makes RGD a pow-
erful vehicle whereby the majority of tumors can be targeted.25,26 Clinically, RGD-based PET 
and SPECT tracers are already extensively investigated in Phase I and Phase II imaging studies, 
revealing their imaging potential, while the peptide (named cilengitide) was investigated for 
its anticancer effects in a Phase III trial in high doses without significant side effects.27–30 We 
used the modified cyclic versions of peptide RGD (cRGDfK, hereafter referred to as cRGD), as 
they possess enhanced clearance, stability and binding affinity. Moreover, they can easily be 
conjugated to various labels without losing their affinity.31  
In this study, we measured the fluorescence lifetime of two clinically relevant tumor-
specific fluorophores developed for FGS using an enhanced camera set-up.32 We examined and 
compared the fluorescence lifetime properties of cRGD-ICG and cRGD-ZW800-1 when bound or 
unbound to αvβ3 during in vitro and in vivo experiments and showed that fluorescence lifetime 
measurements can be a complementary technique utilized next to FGS, ultimately broadening 
the use of NIR fluorescence imaging applications in the clinic. 
MAteRIALs And MetHods 
Tumor-specific agents
cRGD-ICG was produced at the Ecole Polytechnique Fédérale de Lausanne,33 while the cRGD-
ZW800-1 variant was produced in the peptide lab of the Leiden University Medical Center, 
following published protocols.19 Both agents were lyophilized and stored at -80 degrees Celsius 
and diluted when needed.
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Devices used 
Fluorescence lifetimes were acquired with an experimental compact measurement setup, 
named FluoCam (Fig. 1), that measures photon arrival times using an existing single photon 
synchronous detection (SPSD) system enhanced with a precise gating scheme.32 The complete 
time-domain setup consists of a single-photon sensitive sensor array, a picosecond pulsed laser 
for sample illumination, optical components to illuminate the sample and deliver its fluorescent 
signal to the sensor, as well as signal processing and lifetime calculation approaches, allowing 
the complete fine reconstruction of the integral of a fluorescence signal.
The single-photon sensitive sensor itself consists of an array of 60×48 single photon ava-
lanche diodes (SPADs).32 Each SPAD is contained in a pixel, which employs two 8-bit counters 
to record the number of photons detected by the corresponding SPAD in a given time window, 
which can be scanned in time steps as fine as 12.3 ps using programmable delay lines. The need 
for more complex in-pixel electronics entails, in the technology used for FluoCam, a reduced 
fill-factor (0.8%). The overall absolute sensitivity is however sufficient to derive sub-nanosecond 
lifetimes in good agreement with literature, as well as to carry out measurements in vivo. 
The single-photon timing resolution per pixel is of the order of 100 ps, whereas the overall 
system Instrument Response Function has a Full-Width-Half-Maximum (FWHM) of 290 ps. The 
illumination source is a picosecond diode laser (A.L.S. GmbH, Berlin, Germany) with a wave-
length of 790 nm that emits 70 ps FWHM pulses to the sample at a pulse repetition rate of 100 
MHz with an average power of 1.7 mW. The laser trigger signal, delayed through the delaylines, 
is used as a switch between the counters of the SPAD sensor. Two filters (excitation 775/50 
nm (center/bandwidth), emission 845/50 nm) and a dichroic mirror (810 nm) deliver excita-
tion illumination to the sample and emission light to the sensor (filter set No41030, Chroma 
Technology Corporation, Bellows Falls, USA). 
Fluorescence intensity images were acquired with a PEARL imaging system (LI-COR Bio-
sciences, Lincoln, Nebraska, USA) in two spectral bands, which are optimized for two LI-COR 
dyes: the IRDye 680RD (absorbance max 675 nm, emission max 696nm) and the IRDye800CW 
(absorbance max 779 nm, emission max 795 nm). The PEARL is equipped with two excitation 
lasers at 685 nm and 785 nm. Exposure times are by default optimized during imaging. The 
excitation and emission characteristics of ICG and ZW800-1 are sufficiently overlapping with 
IRDye800CW for sensitive fluorescence intensity imaging.
Finally, high resolution fluorescence intensity scanning was performed using the 800 nm 
channel (excitation at 785 nm) of the Odyssey scanner (LI-COR Biosciences, Lincoln, Nebraska, 
USA). This imager is designed for the assessment of in vitro well-plate experiments and the 
imaging of small, excised tissue samples.
108
Chapter 6
Fluorescence lifeti me analysis 
For a specifi c fl uorophore and biochemical environment, the ti me between the absorpti on of 
a photon from a laser pulse and the emission of a photon from the fl uorescent molecule ap-
proximates an exponenti al stochasti c distributi on. The rate at which the fl uorescence intensity 
I decreases over ti me t is parameterized by the fl uorescence lifeti me τ as I(t) = I0e-t/τ, with I0 the 
peak intensity.[8]
In the ti me-domain acquisiti on with the FluoCam experimental setup, two counters (C0 and 
C2) count arriving photons in adjacent intervals that cover the exponenti al distributi on. The 
proporti on of C0 to the total number of arriving photons (C0+C2) depends on the lifeti me τ and 
the user-defi ned delay d. By scanning d over ti me, a histogram that describes the integrated 
exponenti al distributi on is obtained. From this histogram the lifeti me τ is esti mated. Measuring 
with two counters allows for normalizati on in the case of a non-constant fl uorescence intensity 
over ti me, e.g. due to fl uorescence photobleaching. Apart from this normalizati on correcti ons 
are performed to compensate for non-lineariti es in the delay lines. For more details the reader 
is referred to [32-34]. In this paper the processing of the raw signals is slightly changed com-
pared with [32] as described below, to reduce the sensiti vity to noise. The SPADs in the sensor 
were tested to have a photodetecti on probability of 2% at 835 nm.
In this work d is increased in steps of 24.6 ps, which is an opti mizati on between accurate 
lifeti mes and shorter measurement ti mes. In pilot experiments we determined the correspond-
ing acquisiti on range to be suffi  cient to cover the exponenti al distributi ons of the fl uorescent 
probes used. This resulted in a total measurement ti me of almost 3 minutes. The initi al delay is 
adapted on a pixel-to-pixel basis. At each delay, an exposure ti me of 1 second is used.
In the data analysis, the measurements from “hot” (very noisy) and “dead” pixels are 
discarded. Overall lifeti me of the sample is determined from the lifeti mes extracted in each 
individual pixel: an intensity-weighted Gaussian fi t is applied to the corresponding distributi on. 
To reduce the noise, the intensity threshold was set at 3 kcps. However, if a sample could not 
meet that conditi on, the 100 pixels with the highest photon count were taken.
Figure 1. a) The FluoCam measurement setup, used for all experiments. The inset shows the single-photon sensiti ve sensor 
array. Just below that, are the opti cal components that guide the light to illuminate the sample and deliver its fl uorescent sig-
nal to the sensor. The samples are placed underneath the opti cal components. The cooling system and laser are not shown. b) 
The fl uorescence intensity of all pixels of a sample of unwashed cells of 50 µM cRGD-ICG. c) The corresponding fl uorescence 
lifeti me in picoseconds.
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Cell line 
The U87MG glioblastoma cell line was used for the in vitro and in vivo experiments. This cell 
line was previously shown to express the highest number of αvβ3 integrins per cell.[19] The 
U87MG cell line was cultured in DMEM (Gibco, Carlsbad, CA, USA) supplemented with 10% 
fetal calf serum (FCS; Greiner Bio-One, Kremsmünster, Austria), 100U/ml penicillin and 100 U/
ml streptomycin (Gibco) in a humidified incubator with 5% CO2 at 37 degrees Celsius.  
In vitro cell based plate assay
U87MG cells were seeded in black 96-well plates (Greiner Bio-One) at a density of 9.4 x 104 
cells/cm2 and allowed to attach overnight. The following day the cells were incubated with 
a dose range of cRGD-ICG or cRGD-ZW800-1 in DMEM containing 5% bovine serum albumin 
(BSA) or with 50µM probe without BSA in duplicate. After 1 h half of the wells were washed 
with DMEM/5% BSA or DMEM alone (without BSA), while in the other half the probe solution 
remained present during the measurements to create washed and unwashed samples. The 
probe solutions and the incubated wells were measured 3 times using the FluoCam setup. 
Subsequently, the solutions and incubated wells were scanned using the Odyssey Infrared 
Imaging System at a resolution of 42 μm, medium quality and intensity of L1.0-L2.0 (solutions) 
or L1.0-1.0 (incubated wells). Each well was analyzed and the integrated intensity (counts/mm2) 
was calculated using the Odyssey software.
In vivo measurements
Six to eight week-old a-thymic female mice (CD1-Foxn1nu, Charles River Laboratories, l’Arbresle, 
France) weighing 25 - 35 g, were housed in accordance with the guidelines of the Animal Welfare 
Committee of the Leiden University Medical Center. Autoclaved low fluorescence pellet food, 
normal pellet food and sterilized water were provided ad libitum. Throughout tumor inocula-
tion and the measurement procedures, the animals were anesthetized with 4% isoflurane for 
induction and with 2% isoflurane for maintenance with a flow of 0.5 L/min and were placed on 
a heated animal bed with an integrated nose mask. All animal experiments were approved for 
animal health, ethics, and research by the Animal Welfare Committee of the Leiden University 
Medical Center. All animals received humane care and maintenance in compliance with the 
‘Code of Practice Use of Laboratory Animals in Cancer Research’ (Inspectie W&V, July 1999).
To induce subcutaneous tumors, U87MG cells were injected at four sites on the back 
(1,500,000-3,000,000 cells per spot) and tumor growth was monitored using a digital caliper. 
When the tumors were approximately 36mm3, either 30 nM (50 µg) of cRGD-ICG (n=4 mice) 
or cRGD-ZW800-1 (n=4 mice) was injected intravenously. Fluorescence lifetime was measured 
directly (between 15-60 minutes) and at 24 hours. At both time-points two of the four tumors 
were measured. A control spot in the tail (to measure free floating agent) was created by a 
subcutaneous bolus injection of the fluorophore and measured at both time-points. After each 
time-point, mice were simultaneously imaged using a PEARL imaging system to evaluate fluo-
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rescence intensity. The two tumors that were measured directly were resected and quick frozen 
in isopentane to perform NIR fluorescence microscopy and to evaluate probe distribution. After 
the 24 hours measurement mice were sacrificed and the remaining tumors, were quickly frozen 
in isopentane for histological evaluation.
Histology
Tissues were sectioned at 10 µm, mounted with DAPI, and examined for NIR fluorescence signals 
using the Nikon eclipse E800 microscope (Nikon, Amsterdam, The Netherlands). Afterwards 
all histologic sections were stained with standard hematoxylin-eosin stain (HE) to evaluate 
presence of tumor cells and histology. As control, similar tumor tissue from a mouse without 
injection of a probe was also investigated using fluorescence microscopy and HE-staining.
Statistics 
Statistical analysis was performed with SPSS software (IBM SPSS statistics version 22). Vari-
ance between groups was first assessed via one way analysis of variation (ANOVA); differences 
in means between two groups were assessed via the post-hoc Bonferroni test. P<0.05 was 
considered statistical significant. Data are expressed as mean ± standard deviation (SD).
ResULts
In vitro fluorescence lifetimes 
Lifetimes of cRGD-ICG dissolved with BSA either incubated at U87MG cells (washed and un-
washed) or in solution remained stable and showed no significant differences between all three 
concentrations (10 µM, 20 µM and 50 µM), and SDs were low for the solutions and unwashed 
groups (4-8 ps) (Fig. 2a). In the washed group relatively large SDs (17-45 ps) were observed 
probably due to the low signal intensity as shown in Fig. 2c. When BSA is omitted, mean 
lifetimes dropped significantly for all groups (p<0.001). As expected, higher signal intensities 
are observed in the unwashed and solution groups with BSA (Fig. 2c). Fluorescence intensities 
when BSA is omitted are lower (means of 39.9 ± 8.3 A.U., 56.5 ± 3.9 A.U., and 6.2 ± 2.1 A.U. for 
washed, unwashed and solution, respectively) compared to those with BSA.
Lifetimes of cRGD-ZW800-1 dissolved with BSA either incubated at U87MG cells and un-
washed or in solution did not remain stable between all three concentrations. The unwashed 
samples of 50 μM were significantly different from those of 10 and 20 μM (p<0.001 for both). 
The solution samples of 10 and 50 μM were also significantly different (p<0.001). The washed 
samples showed very low fluorescence intensities (Fig. 2d) and although similar lifetimes were 
measured as in the other samples, standard deviations of fluorescence lifetimes were much 
higher (between 46-129 ps compared to 3-16 ps) (Fig. 2b). Significant differences were seen be-
tween solution samples with BSA compared to without BSA (p<0.001) and unwashed samples 
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with BSA compared to without BSA (p<0.001), but not for the washed samples. Fluorescence 
intensities when BSA is omitted were 1.3 ± 0.9 A.U., 180.4 ± 169.8 A.U., and 929.3 ± 274 A.U. 
for washed, unwashed and solution, respectively.
Overall, grouping the different concentrations with BSA (10 µM, 20 µM and 50 µM) did not 
lead to significantly different lifetimes between these groups for cRGD-ICG. For cRGD-ZW800, 
the difference between washed and solutions samples was significant (p=0.023). Photobleach-
ing was observed in the measurements, especially in the pixels with high initial intensity (Fig. 
3a). However the extracted lifetimes of pixels with higher or lower intensity decreases did not 
differ, due to the applied correction (Fig. 3b). We did find that higher overall intensity of the 
sample, caused less variation in extracted lifetime. This explains the higher standard deviations 
and variations of the washed samples compared to those of the unwashed samples and solu-
tions (Fig. 4). 
Figure 2. Lifetimes (ps) of cRGD-ICG or cRGD-ZW800-1 at U87MG cells or in solution. Boxplots show the median, first and 
third quartile, and minimum and maximum lifetimes (ps). a) Data from cRGD-ICG: For 10 µM  mean lifetime values were 
476±45, 502±8 and 494±8 for respectively washed U87MG cells, unwashed U87MG cells or tracer in solution; for 20 µM this 
was 497±29, 495±4 and 496±8; for 50 µM 490±17, 492±5 and 494±5; and for 50 µM without BSA 356±28, 335±33 and 200±51 
(not shown in Figure). b) Mean fluorescent intensities of cRGD-ICG measured with the Odyssey for respectively washed 
U87MG cells, unwashed U87MG cells or tracer in solution. c) Data from cRGD-ZW800-1: For 10 µM mean lifetime values were 
456±129, 461±3 and 469±16 for respectively washed U87MG cells, unwashed U87MG cells or tracer in solution; for 20 µM 
this was 464±61, 466±4 and 480±5; for 50 µM 407±49, 477±5 and 489±4; and for 50 µM without BSA 425±113, 424±8 and 
445±3 (not shown in Figure). d) Mean fluorescent intensities for cRGD-ZW800-1.  
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In vivo fl uorescence lifeti mes and intensiti es 
Aft er intravascular injecti ons of 30 nM of either cRGD-ICG or cRGD-ZW800-1 fl uorescence 
lifeti mes were measured directly (1 h) and 24 h post injecti on in both the tumors and in the 
tail to measure respecti vely bound and unbound agent (Fig. 5). Lifeti mes of cRGD-ICG at the 
tumor were stati sti cally signifi cantly higher than those at the tail at both 1 hour (p<0.001) and 
24 hours (p=0.022) (Fig. 5a). Figure 5b shows representati ve images of opti cal fl uorescence 
imaging with high signals in the liver and moderate to low signals in the tumor at 1 h (mean 1.5 
± 0.03 A.U.) and at 24 h (mean 1.6 ± 0.08 A.U.).
Interesti ngly, the opposite is true for lifeti mes of cRGD-ZW800-1: lifeti mes at the tail were 
stati sti cally signifi cantly higher than those at the tumor aft er both 1 hour (p<0.001) and 24 
hours (p=0.036) (Fig. 5c). Using opti cal fl uorescence imaging high signals were observed in the 
kidneys and tumors could be recognized with moderate mean TBRs (1.1 ± 0.06 A.U. at 1 h and 
1.9 ± 0.27 A.U. at 24 h) (Fig. 5d).  
Figure 3.a) Example of the intensity change per pixel over the measurement ti me, measuring a sample of unwashed cells 
of 50 µM cRGD-ICG. b) The corresponding extracted lifeti me per pixel. As the lifeti me analysis corrects for photobleaching, 
extracted lifeti mes are not infl uenced by the change in intensity over ti me. 
Figure 4. Two examples of the extracted lifeti me versus the pixel intensity. a) Unwashed sample of 50 μM cRGD-ICG. b) 
Washed sample of 50 μM cRGD-ICG.
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Histology 
Resected tumors and tails were investigated using fluorescence microscopy and HE-staining for 
presence and locations of the agents (Fig. 5). Both agents showed clear tumor specific signals, 
which were homogeneously distributed throughout the tumor and mainly located intracellu-
larly in the cytoplasm. NIR fluorescence in the tail sections was mainly recognized in localized 
spots, located intercellularly and/or on endothelial cells. Generally, no homogeneous specific 
binding was observed in the tail sections, validating its use as control measurement point. The 
control tumor showed no specific signals at all.
Figure 5. Lifetimes and fluorescence intensity images of mice injected with 30 nM of either cRGD-ICG or cRGD-ZW800-1. Box-
plots show the median, first and third quartile, and minimum and maximum lifetimes (ps) a) Using cRGD-ICG mean lifetimes 
in the tumors were 508±7 and 490±31 at respectively 1 h and 24 h (both 24 measurements). In the tail those were 493±12 
and 477±12 (both 12 measurements). b) Examples of fluorescence intensity images with cRGD-ICG captured at 1 h and 24 h. 
TBRs are from the showed image. The areas in the red circles represent the tumor and background (with asterisk) signal used 
to determine the TBR. c) Using cRGD-ZW800-1 mean lifetimes in the tumors were 520±8 and 457±37 at respectively 1 h and 
24 h (both 24 measurements). In the tail those were 574±9 and 530±73 (both 12 measurements). d) Examples of fluorescence 




In this study we measured and analyzed the lifeti mes of two RGD-based clinically relevant 
fl uorophores – cRGD-ICG and cRGD-ZW800-1 – and evaluated and compared the ability to dif-
ferenti ate between their bound (tumor specifi c) and unbound (aspecifi c) state in vitro and in 
vivo. The most important result of this research was the fi nding that in vivo both fl uorophores 
showed reproducible fl uorescence lifeti mes that were signifi cantly diff erent between the 
tumors and control regions. 
Lifeti mes were measured using the FluoCam ti me-domain SPAD-based system, which is a 
prototype recently developed and described by Homulle et al.32–34 Using a SPAD array, enhanced 
with a gati ng scheme, and combined with a picosecond laser, the setup is able to both derive 
fl uorescence intensity, as well as sub-nanosecond fl uorescence lifeti mes in vivo. Qualiti es of 
the system are the excellent single photon ti ming resoluti on, its compactness, low power and 
low voltage-operati on. However, during in vitro plate assay experiments where a single cell 
Figure 6. The left  column shows HE-stained secti ons of either the tumors or tails. DAPI staining was used to visualize cell 
nuclei to fi nd the corresponding spot at the HE slide. NIR fl uorescence microscopy and the DAPI-NIR merge image shows the 
specifi c locati on of the fl uorescent spots. Both cRGD-ICG and cRGD-ZW800 shows a homogeneous distributi on throughout 
the tumor (bound agent), while the tail shows localized fl uorescent spots mainly intercellular located (unbound agent) and 
sporadic at endothelial cells. No fl uorescence signal is seen in the control tumor.
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layer of tumor cells are targeted, the system had difficulty with detecting the low signal intensi-
ties in the washed groups, resulting in large standard deviations. It is feasible to make the 
next generation system 50 times more sensitive (e.g. improving the fill-factor at the pixel level 
and increasing the photon detection probability in the NIR). This would allow a lower dose of 
fluorescent probe, decreased duration of measurements and lower standard deviations.
Interestingly both fluorophores reacted differently after binding: the lifetime of cRGD-ICG 
increased, while that of cRGD-ZW800-1 decreased; this phenomenon was significant in vivo, 
but not in vitro. We believe that the in vitro results for the washed samples are not representa-
tive. In the first place, our device was not sensitive enough to capture enough signal to extract 
reproducible lifetimes in the washed samples that suffered from low fluorescence intensities. 
This is supported by the more stable extracted lifetimes found at pixels with higher intensity 
(Fig. 4). Secondly, Ardeshipour et al.35 already recognized the difficulty in measuring binding 
effects in vitro and argued that it is not only the binding causing the lifetime changes, but a 
combination of several processes, also involving the binding to serum albumin. For that reason 
we added BSA during our in vitro experiments resulting in reproducible results. Omitting BSA 
showed decreased fluorescence lifetimes for both fluorophores. However, the effect on cRGD-
ICG was larger compared to cRGD-ZW800-1 (average difference of 156 ps vs 32 ps, respectively), 
which could be explained by the neutral net charge and high hydrophilicity of ZW800-1 and the 
net charge of -1 and hydrophobic character of ICG.36–38 The influence of albumin on lifetime was 
also described in a paper by Mathejczyk et al., who attributed this effect to an increased rigidity 
of the fluorophore, and a reduced polarity of the fluorophore’s local environment.39 Thereby, 
binding to albumin prevents close contact between the fluorophore and water molecules.
In vivo results showed that mean fluorescence lifetimes for cRGD-ICG in the tumor were 
508 ± 7 ps after 1 hour. This is slightly shorter (but in a comparable range) than the lifetime 
of ICG bound to albumin, which lies around 600 ps.40,41 The effect that we observed – a higher 
lifetime in tumor compared to control tissue (mean fluorescence lifetime of 493 ± 12 ps) – was 
similar to that of Bloch et al., who investigated cypate – a structural analog of ICG – bound to 
cRGD.15 Mean fluorescence lifetimes for cRGD-ZW800-1 were 520 ± 8 at 1 h, approximately 10% 
lower compared to the tail. Ardeshipour et al., also found a shorter lifetime in tumor compared 
to the control site.14 They measured lifetime of AlexaFluor 750, which possesses good water 
solubility42 just like ZW800-1, probably explaining the comparable mechanisms. Although both 
for cRGD-ICG and cRGD-ZW800-1 the differences in lifetime between tumor and control are not 
very large (4-10%), they are reproducible and significant. 
For the in vivo measurements the glioblastoma U87MG xenograft mouse model was used as 
it expresses high levels of αvβ3. As the RGD motive and integrins are evolutionary conserved43, 
both cRGD-based agents recognized murine integrins in our U87MG xenograft mouse model, 
making it clinically relevant. The tail was used as a control spot for the unbound probe. His-
tology confirmed the difference in distribution and binding between tail and tumor for both 
fluorophores. It is to be expected that the differences in lifetime between tumors and closely 
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surrounding tissue are smaller than tumors and the tail. It should be kept in mind that our 
goal in this study was to create the largest difference possible in binding of the fluorophore, to 
study whether it was feasible to find a lifetime difference at all. Future research, using a more 
sensitive system, could for example look at muscle tissue, where the αv subunit is known to be 
absent, to get a more representative control spot.
Eventually we think that the clinical applicability of this technique will primarily be next to 
FGS as it can aid in differentiating between specific bound and unbound tracer. For example, 
when a fluorescent hotspot is shown during surgery and the treating physician is not sure 
whether the signal is specific, fluorescence lifetimes could be measured to evaluate if the agent 
is specifically bound or not. Furthermore, as fluorescence lifetime could be applied in signifi-
cant shorter imaging windows than FGS, it could function as a stand-alone technique provided 
that sensitivity, resolution and imaging speed are significantly increased. 
This study added evidence that tumor-bound fluorescent agents can be distinguished from 
non-tumor bound agents in vivo. In particular, we showed this for two fluorescent agents that 
approach clinical translation. We also showed that lifetimes measured in comparable settings 
and set-up can either decrease or increase when bound, depending on the fluorophore that 
is used. These results are an encouragement to optimize fluorescence lifetime acquisition for 
clinical implementation, especially by improving the overall system sensitivity. 
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 Summary, discussion and future perspectives
In this thesis we studied the feasibility of three optical imaging techniques to differentiate 
tumor tissue from its surrounding tissue for various clinical purposes.
In chapters 2, 3 and 4 we looked at full field optical coherence tomography. FF-OCT im-
ages with high-resolution (1 μm) provide en face images, depend on endogenous contrast and 
achieve an imaging depth up to 500 μm (depending on the imaged tissue). Although the resolu-
tion might be high, the contrast is based on backscattering differences without being highly 
tissue specific. Therefore, distinguishing intracellular structures or cytonuclear details is not 
possible. Also, currently FF-OCT images need to be assessed by a pathologist, which requires 
extensive training. 
FF-OCT is a promising non-destructive technique to image and select cortical ovarian 
tissue strips, but requires more research to determine its potential contribution to improved 
pregnancy rates. 
In chapter 2 we imaged cortical ovarian tissue strips, which are used to preserve fertility 
in women that undergo chemotherapy and are at risk of premature ovarian failure. We found 
that FF-OCT did not harm the viability of the tissue and had sufficient resolution to detect 
both normal ovarian structures and metastases in human tissue samples. In addition, FF-OCT 
facilitates the selection of cortical ovarian tissue with the highest density of primordial follicles. 
For these reasons we believe that this application fits the FF-OCT technique very well, more so, 
because current techniques that are used to detect metastases in ovarian tissue are destruc-
tive, meaning that the tissue cannot be autotransplanted anymore. 
Due to the small sample size we did not validate the sensitivity and specificity with which 
pathologists could distinguish normal from tumor tissue. Also we did not validate the minimal 
size of a micrometastases that could still be detected with FF-OCT. Future research should focus 
on these outstanding issues. Thereby, the most meaningful outcome in the field of fertility 
preservation is ultimately a successful pregnancy. So pregnancy rates following exposure to 
FF-OCT also need to be evaluated. 
FF-OCT can be used for margin detection, but should be further improved with better 
contrast, more training and computer aided diagnosis
In chapters 3 and 4 we studied FF-OCT in breast and pancreas aiming to eventually apply it 
for margin detection. The current overall accuracy we reached (79% in breast tissue and 73% in 
pancreatic tissue) is not yet sufficient. We believe that there are three important measures that 
have to be taken in order to improve diagnostic accuracy: (1) better contrast, (2) more extensive 
training and (3) computer aided diagnosis. 
Contrast can be increased by dynamic cell imaging: a technique that enhances the cellular 
contrast by capturing the microscopic intracellular movements in freshly excised tissue [1]. 
This technique, that can capture metabolic states of cells is complementary to the existing 
FF-OCT technique. Thouvenin et al., were able to reveal subcellular details such as the nucleus 
position and size in retinal tissue [2]. Moreover, very recently, Yang et al. [3], used both FF-OCT 
and dynamic cell imaging to image breast and nodal tissue. Both specificity and sensitivity 
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differentiating normal from benign tissue were higher with dynamic cell imaging compared to 
only FF-OCT. 
More extensive training combined with computer aided diagnosis could help as well to 
improve reading accuracy of current images. For example, earlier studies on reading of pros-
tate images showed a learning curve from 60% to 80% [4] within one study, which further 
improved to 93% in a second study [5]. Computer aided diagnosis can take advantage of the 
highly scattering collagen, making tumor stroma evidently visible in both breast and pancreatic 
tissue. This concept has been proven effectively by Bredfeldt et al., who used tumor associated 
collagen signatures of breast cancer tissue to automatically detect the tissue type, reaching 
an overall accuracy of 91.9% [6]. Focusing on collagen topography could even give additional 
information, as it is associated with a patients prognosis [7]. 
Single fiber reflectance spectroscopy has the potential to guide biopsies but requires 
larger sample size studies and real-time feedback
In chapter 5 we applied single fiber reflectance spectroscopy in endoscopic ultrasound-
guided fine needle aspirations (EUS-FNA) of pancreatic masses. The specifications of this 
technique such as a very small field of view and low penetration depth, might be very disadvan-
tageous for most applications but fits the purpose of biopsy guidance perfectly. EUS-FNA suffers 
from sample errors and low-negative predictive values. However, as neoadjuvant therapy gains 
more interest, which requires a pathological diagnosis, it is highly important to reduce the 
sampling error and increase the negative predictive value of EUS-FNA procedures. 
We found significant differences in blood volume, blood saturation and bilirubin levels 
between tumor and surrounding tissue. However, we only performed a feasibility study with 
a small sample size. Future studies should increase the number of patients included to vali-
date the first results found and to increase the knowledge on the characteristics of different 
pancreatic tissues. Next to that, for a clinical embedding of the technique, it needs to deliver 
real-time feedback to the physician. Since our spectral fitting method is sufficiently fast (<1 s), 
this is feasible. Moreover, recently a new spectral fitting model was developed which predicts 
the measured reflectance substantially better than the model used in this study [8]. This can be 
used in the next study with larger sample size. 
Fluorescence lifetime could potentially be used in parallel to fluorescence guided surgery, 
but needs large technical improvements
In chapter 6 we looked at fluorescent lifetime measurements (FLM) and investigated the 
ability to differentiate between their bound, tumor-specific, and unbound, aspecific, state. 
Where in the first four chapters we looked at endogenous contrast – contrast of the tissue 
itself – this technique exploits exogenous contrast agents. It is also the technique that is the 
least developed for clinical applications out of the three techniques studied in this thesis. 
Fluorescence lifetime measurements can be used in parallel to fluorescence guided surgery 
(FGS) and overcome some of the demerits of FGS such as the high wash-out time of unbound 
agents and a low overall tumor-to-background ratio. In our study, we found small differences 
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between bound and unbound tracer (4-10%), but they were reproducible and significant. Due 
to the low sensitivity of the system, in-vitro measurements lacked clear signals which resulted 
in high standard deviations for the lower concentrations. The sensitivity of the system clearly 
needs work. We were only able to show small differences between tumor tissue and a spot in 
the tail (unbound), but it will be harder to show differences between tumor tissue and close by 
tissue that is normal. If sensitivity can be drastically improved and differences between tumor 
and surrounding tissue are found, further steps can be taken to think about ease of use, way of 
(real-time) feedback and integration into FGS.
Optical imaging techniques studied in this thesis could be of additional clinical value, but 
translation to clinical practice is far off
In this thesis we studied the feasibility of three optical imaging techniques to differentiate 
tumor tissue from its surrounding tissue for various clinical purposes. Our main research ques-
tion hereby was: 
Is it feasible to differentiate tumor tissue from surrounding tissue using optical imaging 
techniques; and which technique can be of added value for clinicians in which clinical situation? 
We concluded that both full field optical coherence tomography and single fiber reflectance 
spectroscopy could either with help of pathologists or by signal analysis differentiate tumor tis-
sue from its surrounding tissue. Although FF-OCT is especially useful in imaging ovarian tissue, 
endogenous contrast in breast and pancreatic tissue is not yet sufficient. Using fluorescence 
lifetime we were able to demonstrate differences between tracer bound to tumor cells and 
tracer not bound to tumor cells. However, this technique is still much more experimental and 
with the current technique, differentiating tumor tissue from its directly surrounding tissue is 
not yet possible.
Next to the techniques studied in this thesis, many other optical techniques are studied to 
image tissue physiology and pathology, such as Raman-spectroscopy, hyperspectral and short-
wave infrared imaging. Although a lot of research is performed on all these techniques, only 
few will translate to the clinic: the gap from feasibility to standard of practice is massive. In 
this thesis we only studied the feasibility, but did not perform larger scale multi-center studies. 
Naturally this is an important requirement to bring research one step closer to clinical adop-
tion. Furthermore, the added technique should match current clinical workflow as closely as 
possible. 
For instance converting an FF-OCT image with dynamic cell imaging into a H&E staining 
image(e.g. by using a Generative Adversarial Network, deep learning technique), will be better 
recognized by pathologists. Just like a fiber incorporated into a biopsy needle to immediately 
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sAMenvAttInG
Beeldvorming speelt een cruciale rol in de oncologie. Het wordt gebruikt om de diagnose te 
stellen, biopten te begeleiden, het effect van behandeling te monitoren, chirurgische ingrepen 
te plannen en het verloop van de ziekte te voorspellen. CT, MRI, röntgenfoto´s en echografie 
zijn voorbeelden van beeldvormende technieken die veel gebruikt worden, voornamelijk voor 
anatomische informatie. De meer recent geïntroduceerde positronemissietomografie (PET) en 
single photon emission computed tomography (SPECT) scans, geven voornamelijk functionele 
informatie. Verbeteringen van deze technieken hebben geleid tot meer precieze, snellere en 
minder invasieve beeldvorming. Helaas komen al deze beeldvormende technieken met hun 
eigen beperkingen met betrekking tot resolutie, sensitiviteit en de mate van contrast, waardoor 
ze niet voor alle toepassingen geschikt zijn. Bovendien zijn ze, afgezien van Röntgen en echo-
grafie, relatief duur en is real time imaging beperkt. Daarom wordt er veel onderzoek gedaan 
naar optische beeldvormende technieken.
Optische beeldvorming bevat een brede range van technieken die licht gebruiken in het ul-
traviolette spectrum (315-400 nm), het zichtbare spectrum (400-700 nm), het nabije infrarode 
spectrum (700-1400 nm) of in het korte golf infrarode spectrum (1400-3000 nm) om moleculaire, 
morfologische en functionele informatie te geven over cellen of weefsels. Enkele voorbeelden 
van optische technieken zijn endoscopie, nabij-infrarode fluorescentie, optische coherentie 
tomografie, foto-akoestische beeldvorming, Raman spectroscopie en diffuse spectroscopie. De 
voordelen van deze technieken zijn sterk afhankelijk van welke techniek je gebruikt voor welke 
toepassing, maar algemene voordelen zijn het goede contrast in zacht weefsel, hoge resolutie, 
niet-invasieve aard en apparatuur die relatief goedkoop en makkelijk te hanteren is. Algemene 
nadelen zijn de beperkte penetratiediepte en het relatief kleine gezichtsveld.
In dit proefschrift bestuderen we de haalbaarheid van drie optische beeldvormende 
technieken om tumorweefsel van het omliggende weefsel te herkennen, voor verschillende 
klinische toepassingen.  
In hoofdstuk 2 tot en met 4 bestuderen we full-field optische coherentie tomografie 
(FF-OCT) in eierstok-, borst- en alvleesklierweefsel. Optische coherentie tomografie (OCT) is 
vergelijkbaar met echografie, maar detecteert terugkaatsend licht in plaats van terugkaatsend 
geluid. De resolutie van OCT is 10-50 keer beter dan die van echografie (1-20 µm in axiale en 
transverse richting) en is net als echografie niet invasief en niet destructief. In plaats van de 
dwarsdoorsneden die met OCT worden berekend, maakt FF-OCT en face beelden met hoge 
resolutie (1 μm). Het systeem dat in dit proefschrift gebruikt is, bestaat uit een staande mi-
croscoop en een referentiearm in een Linnik interferometrische opstelling. De lichtbron is een 
witte halogeenlamp van 150 watt, met een centrale golflengte van 700 nm en een spectrale 
breedte van 125 nm. Het contrast in de beelden komt door het terugkaatsende licht van het 
weefsel, maar is niet heel erg weefselspecifiek. Daardoor zijn, ondanks de hoge resolutie, 
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intracellulaire structuren of details van de celkern niet te onderscheiden. De FF-OCT beelden 
moeten worden beoordeeld door een patholoog, wat uitgebreide training vergt.
Uit het onderzoek, beschreven in hoofdstuk 2, blijkt dat het contrast en de resolutie van FF-
OCT voldoende waren om uitzaaiingen in eierstokweefsel én verschillende ontwikkelingsstadia 
in de eicellen zichtbaar te maken. Daarnaast bleek dat het afbeelden de vitaliteit van zowel het 
weefsel als de eicellen niet aantast. Dit zijn belangrijke bevindingen voor een vruchtbaarheids-
besparende behandeling bij vrouwen, waarbij eierstokweefsel wordt ingevroren en weer wordt 
teruggeplaatst. Wanneer een patiënt direct moet starten met chemotherapie of bestraling is dit 
de enige behandelingsmogelijkheid waarbij de eierstokfunctie kan worden hersteld. Dit brengt 
echter het risico mee dat je tumorcellen herintroduceert, in het geval dat deze al naar de eier-
stok was uitgezaaid. Met FF-OCT zou je niet alleen kunnen controleren of er uitzaaiingen in het 
terug te plaatsen weefsel zitten, maar ook het weefsel kunnen selecteren met de beste kans op 
herstel van de eierstokfunctie. Kanttekeningen bij dit onderzoek zijn het relatief kleine aantal 
weefselfragmenten dat we hebben afgebeeld waardoor we niet de sensitiviteit en specificiteit 
waarmee de patholoog tumorweefsel kon onderscheiden in kaart gebracht hebben. Ook heeft 
FF-OCT een beperkte penetratiediepte van maximaal 100 µm in dit type weefsel, waardoor je 
niet het hele weefselfragment af kunt beelden. 
In hoofdstuk 3 en 4 hebben we het gebruik van FF-OCT in borst- en alvleesklierkanker 
onderzocht, om daar uiteindelijk de tumormarges mee af te beelden tijdens de operatie. De 
nauwkeurigheid waarmee pathologen tumor- van normaal weefsel kunnen onderscheiden op 
basis van de FF-OCT beelden was 79% in borstweefsel en 73% in alvleesklierweefsel. Dat is 
uiteraard niet genoeg voor een klinische toepassing. We denken wel dat deze nauwkeurigheid 
verder verhoogd kan worden door een aantal maatregelen: beter contrast, betere training van 
pathologen en computerondersteunde diagnose. 
In hoofdstuk 5 concluderen we dat het toevoegen van single fiber reflectie spectroscopie-
metingen mogelijk is bij het nemen van een endoscopische echogeleide punctie (EUS-FNA) in 
de alvleesklier. Een nadeel van de huidige EUS-FNA procedure is de lage negatief voorspellende 
waarde van het onderzoek: als er geen tumorcellen worden gevonden, betekent dat niet dat 
ze er niet zijn. Helemaal nu neoadjuvante therapie – waarvoor een pathologische diagnose 
nodig is – steeds meer belangstelling krijgt, is het belangrijk om op de goede plek een punctie 
te nemen. Specificaties van single fiber reflectie spectroscopie zijn onder andere een klein 
gezichtsveld en een beperkte penetratiediepte, wat voor het nemen van puncties zeer geschikt 
is. De metingen worden genomen door een enkele fiber, die door een punctienaald past. 
Met spectroscopiemetingen toonden we significante verschillen aan in bloedvolume, 
bloedsaturatie en bilirubinegehalte tussen tumorweefsel en omliggend weefsel. Deze metin-
gen kunnen de gastro-enteroloog helpen bij het vinden van een goede plaats om een punctie 
te nemen. In deze studie hebben we echter maar 16 patiënten geïncludeerd. Verder onderzoek, 
met meer patiënten is nodig om deze eerste resultaten te valideren. Daarnaast hebben we in 
deze studie de metingen achteraf geanalyseerd. Voor klinische toepasbaarheid heeft de arts 
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real-time feedback nodig. Dit is gelukkig al wel mogelijk met de huidige fittingmethode, maar 
meer data is nodig om te herkennen wat tumorweefsel en wat omliggend weefsel is. 
In hoofdstuk 6 zagen we dat we met fluorescence lifetime metingen een onderscheid kon-
den maken tussen gebonden – tumor-specifiek – en ongebonden fluorescent contrastmiddel. 
Waar we in de hoofdstukken hiervoor keken naar het endogene contrast van weefsel, gebruikt 
deze techniek exogeen contrastmiddel. Deze techniek kan gebruikt worden als aanvulling op 
fluorescentie-geleide chirurgie. In deze studie vonden we kleine verschillen (4-10%) in de 
fluorescente levensduur (een eigenschap van het contrastmiddel die afhangt van de omgeving) 
van contrastmiddel dat gebonden was aan de tumor en contrastmiddel dat ongebonden was. 
Hoewel de verschillen klein waren, waren ze wel significant en reproduceerbaar. Echter, door 
de lage sensitiviteit van het meetsysteem, was het signaal van de in-vitro-metingen zeer zwak 
wat resulteerde in grote variaties bij lage concentraties. Daarnaast zagen we alleen verschil bij 
in-vivo metingen tussen contrastmiddel in de staart (geheel ongebonden) en contrastmiddel 
in de tumor (geheel gebonden). De verschillen tussen tumorweefsel en omliggend weefsel, in 
een meer realistisch scenario, zullen moelijker zijn om aan te tonen. Daarvoor moet eerst de 
sensitiviteit van het systeem drastisch verhoogd worden.
Uit de voorgaande hoofdstukken blijkt dat FF-OCT en reflectie spectroscopie potentieel 
kunnen helpen om tijdens een operatie of endoscopische procedure tumorweefsel te onder-
scheiden van het omliggende weefsel. Met fluorescence lifetime metingen kan dat nog niet. 
Verdere technische verbeteringen in gebruik, analyse en presentatie van de metingen zijn nog 
nodig en daarnaast grootschaliger patiëntenstudies voordat ze kunnen worden opgenomen in 




Onderzoek doe je niet alleen. Ik maak dan ook graag van deze gelegenheid gebruik om iedereen 
die heeft bijgedragen aan dit proefschrift te bedanken.
Ten eerste ben ik dankbaar voor iedereen die als patiënt meewerkt aan medisch onderzoek. 
Ik vind het elke keer bijzonder hoe gemotiveerd patiënten zijn om bij te dragen aan het verbe-
teren van behandelingen waar ze (vaak) zelf geen baat bij hebben.
Jouke, Alexander, Boudewijn en Cock, bedankt voor de kans die jullie mij hebben gegeven 
en de prettige begeleiding tijdens mijn onderzoek. Collega’s van het LKEB (speciale dank aan 
kamergenoten van de terminaalzaal) en de oncologische chirurgie: bedankt voor de voetbal-
toernooien, bbq’s, gezamenlijke congresbezoeken, borrels en prettige werkdiscussies. Ook veel 
dank aan alle andere collega’s binnen het LUMC die hebben bijgedragen, met name vanuit de 
afdelingen pathologie en MDL. 
Niet alleen collega’s binnen het LUMC, maar ook collega-onderzoekers daarbuiten hebben 
bijgedragen aan dit proefschrift. Met name dank aan alle partners van het CAReIOCA-project, 
het Erasmus MC en de TU Delft.
Ontspanning is minstens zo belangrijk als werk en daar hebben ook veel mensen aan bijge-
dragen. Veel dank daarvoor aan vriendinnen, vrienden, teamgenoten en familie. Papa, bedankt 
voor het meedenken, meelezen en het relativeren. Evert, bedankt voor alles! 
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